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SUMMARY 
The clinical phannacoldnetic properties of NSA1D's are markedly influenced by the 
affinity and extent of their protein binding properties in plasma and synovial fluid. 
Whilst the total level of NSAID is dependent upon concentration and affinity of local 
protein, it is the unbound / free fraction that is the species which readily diffuses 
between plasma and synovial fluid. The synovial fluid kinetics of the NSAlD's 
have received remarkably little attention until recent years, despite the increasing 
accumulation of evidence casting doubt on a consistent pharmacoldnetic correlation 
between plasma concentrations of NSAID's and respective analgesic / anti - 
inflammatory activity. This study examined the effect of some physical and 
environmental factors on the protein binding of pircodcam and ibuprofen in synovial 
fluid. 
In this current work, the Amicon MPS-1 ultrafiltration device provided rapid and 
consistent separation of unbound NSAID in synovial fluids and HSA solutions. 
Radiolabelled pirmdcam provided a convenient and relatively simple means of 
measuring the free fraction of this drug in synovial fluid using this device, with a 
coefficient of variation of 9.8%. 
The 2-arylpropionic acids include some marketed and commonly prescribed 
NSAID's. They possess a chiral centre, are stereospecific in action and may 
undergo metabolic inversion from the inactive R-(-) to the active S-(+) enantiomer. 
The prostaglandin inhibitory effect resides with the S-(+) enantiomer, yet with the 
exception of S-(+) naproxen, these agents are generally administered as racemic 
mixtures. The extent of metabolic chiral inversion in man is variable and may be one 
very important factor in explaining the variability in response to these agents.Despite 
the fact that the enantiomers of the 2-arylpropionic acid NSAID's differ in 
pharmacological properties, we are still witnessing articles in the literature that 
generate data of a non stereospecific nature. 
In order to characterize the protein binding of the enantiomers of the chiral NSAID's 
(ibuprofen and ketoprofen) in synovial fluid, a GC/MS assay procedure was 
developed that was capable of determining ibuprofen enantiomer concentrations of 
2ng/mL with a coefficient of variation of 5_ 10.8% and 7.4% for s-ibuprofen and 
r-ibuprofen respectively. The entire procedure (complete in a matter of minutes), 
was in marked contrast to the more lengthy methods found in the literature. The 
procedure was readily adaptable to allow resolution of ketoprofen enantiomers with 
a similar degree of sensitivity. 
The free fractions of piroxicam and ibuprofen enantiomers were found to be 
markedly dependent upon their respective drug and associated albumin 
concentrations in synovial fluid according to pre-determined physical conditions. 
Binding of piroxicam was found to be independent of pH at concentrations of drug 
and albumin typically found in synovial fluid. There were marked differences in the 
extent of binding of ibuprofen enantiomers to human serum albumin (HSA) 
solutions, "fatty acid - stripped" HSA solutions, and synovial fluid. The current 
studies suggest that caution with interpretation of binding constants determined from 
experimental data (in these and similar studies), is essential, as most of the 
commonly calculated values are based on saturation functions such as those 
described by Scatchard and Klotz. Consideration should also be given to alternative 
mathematical functions when interpreting the results of non-saturated binding 
studies. 
As synovial fluid is close to the target tissue where a NSAM's effect is exerted, it is 
reasonable to expect its concentration in this fluid to be a better indicator of drug 
activity in rheumatic disease than in plasma. However, before an attempt to 
correlate synovial fluid NSA1D concentration with clinical response can be made, 
consideration of the physical and environmental parameters affecting the protein 
binding of the whole class of these drugs in synovial fluid may be beneficial. 
This thesis contains no material which has been accepted for the award 
of any degree or diploma in any University or College. 
To the best of my knowledge and belief, this thesis contains no material 
previously published or written by another person, except when due 
reference is made in the text of this thesis. 
Damon S. Jack 
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1  ON STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAID's) 
1.1.1 Background 
These are amongst the most commonly prescribed drugs in our community 8 . 
Phenylbutazone, indomethacin and later ibuprofen, were the first of this "new" class 
of drugs of the early 1960's to compete with aspirin in the treatment of rheumatic, 
traumatic and other related disorders. In more recent times, a multiplicity of other "me 
too" NSAID's have evolved - essentially with promise of improved efficacy and/or 
tolerability. Most of these later drugs are systematic developments of earlier NSAID's 
following careful consideration of such factors as drug transport through biological 
membranes, atomic/spatial molecular structure determining receptor "fit", etc. Many 
of these criteria contribute to the development of what the individual pharmaceutical 
companies contend to be a unique drug species, representing a major advance towards 
the relief of the symptoms of rheumatic disease. The reality is that aside from a few 
potentially notable exceptions*, there is essentially little between them in terms of 
spectral activity. This skepticism is further expressed by bodies such as the Australian 
regulatory authorities who on many occasions have either rejected or suspended 
judgment on a number of newer NSAID's (though marketed in numerous other 
countries), on the grounds of lack of convincing evidence of efficacy or safety and 
demonstrable advantages over currently registered NSAID's. 
* A recent symposium reviewed the effects of NSAID's on cartilage destruction,neutrophil 
activation and the immune system. Many NSAID's exhibited important differences concerning their 
respective influence on these parameters.9 
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It is therefore not surprising to learn of an increased interest in the physical and 
pharmacoldnetic parameters of these drugs in an atempt to shed further light on why 
some NSAID's appear to work beter than others in certain patients and disease states. 
Few studies, for example, have tried to assess the possible efects of rheumatoid 
arthritis on drug disposition in patients59. 
Clearly, a closer examination of these drugs at or near their asumed site of action is 
waranted, (Fig 1.1). 
1.1.2 Synovial Distribution of NSAID's 
Most NSAID's (except aspirin) are extensively protein bound (Table 1.1). When 
tissues are inflamed, proteins extravasate from capilaries into adjacent tissues. 
Free or unbound NSAID tends towards difusional equilibrium acros the synovium, 
whilst larger solutes pass unidirectionaly from plasma to synovial fluid and finaly to 
lymphatic vessels, (Fig 1.1): 
Synovial tissue would appear to be the ideal point at which to study the effects of 
anti-rheumatic drugs on target organs as data in this area have been amazingly scant. 
This may in fact be partly due to the obvious practical limitations in obtaining 
sufficient,consistent and uniform samples for analysis. Synovial fluid on the other 
hand is close to the target organ and provides a clearly more practical means of 
monitoring drug activity (using intra-articular catheters or repeated athrocentesis) than 
does analysis of tissue specimens taken by percutaneous synovial biopsy or surgical 
synovectomy. 
The synovial fluid kinetics of the NSAID's have received remarkably little attention 
until recent years, despite the increasing accumulation of evidence casting doubt on a 
consistent pharmacokinetic correlation between plasma concentrations of NSAID's 
and respective analgesic / anti-inflammatory activity 12. 
In general, NSAID synovial fluid kinetics are influenced by the physico-chemical 
properties of the individual drug concerned. For example, the larger the molecule, the 
slower the rate of diffusion - salicylates for instance are said to diffuse more readily 
than larger NSAID molecules such as indomethacin 12 . As most of the clinically 
available NSA1D's are acidic with pk a 's between 3.5 and 6.5 (see Table 1.1), an 
increase in synovial fluid acidity means that these weak acids become progressively 
less ionised and therefore more readily cross membranes and accumulate in inflamed 
tissue by the cliffusional process°. This has been exquisitely demonstrated by Gray 
and co-workers using radio-labelled phenylbutazone and antipyrine in the carageenan 
rat paw inflammation modelil. 
Whilst the fraction of free or unbound anti-rheumatic drug remains fairly constant in 
plasma, it would seem unreasonable to attempt extrapolation of such data to synovial 
fluid. Factors such as variable total protein content, individual protein fraction and 
exudate/transudate may cause respective free drug fractions to vary disproportionately 
with those in the plasma. In addition, NSAID's take longer to reach peak levels in 
synovial fluid as compared to plasma, as illustrated in Table 1.1: 
Table 1.1: PROPERTIES OF SOME ORAL ANTI - RHE1TM4 TICS # 
Mot. pKa t 1/2 	 Protein 	 Serum/S.F 	 S.F/Serum 	 Solubility 
Wt. 	 (hrs) Binding Time to Peak 	 Mean Concn 	 (water) 
( %) 	 ( hours ) 	 Ratio 
Indoie derivatives 
Indomethacin 358 4.5 2.4 99 1 / 2 4.00 
Oxicams 
Piroxicam 331 5.1 36-45 99 0.43 virt.insol 
Tenoxicam L6/10.1 
Phenyiacetic acids 
Diclofenac (im) 318 3.9 1.8 99 soluble 
Propionic Acids 
Flurbiprofen 244 4.2 3.8 99 1.5 / 3-9 0.44 
Ibuprofen 206 5.2 2.5 99 1.5 / 3-4 0.41 virt. insol 
Ketoprofen 254 1.8 60-95 1-3 / 5-6 0.61 
Naproxen 230 4.2 13 99 0.74 virt. insol 
Pyrazoies 
Phenylbutazone 308 4.5 70 95 virt. insol 
Salicylates 
Aspirin 180 3.5 0.25 49 0.55 / 1.15 0.04 soluble 
Salicylate 138 3 3-5 87 1.5 / 2.2 soluble 
# adapted from Walis & Sirnkin12 and Furst5 
S.F = synovial fluid, t112 = plasma half life 
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Whilst most NSAID's have similar pKa' s and protein binding properties, there are 
considerable differences in plasma t 	 's , (the majority being relatively short ). For 
example, diclofenac reaches maximal plasma levels within an hour or so (roughly in 
agreement with the perceived onset of analgesia), then steadily declines whilst 
simultaneous synovial fluid concentrations (essentialy responsible for the 
anti-inflammatory effect), take about four hours to reach maxima. Whilst drug levels 
are relatively lower in synovial fluid compared to plasma, they persist at a 
substantialy higher concentration for a longer period of time after dosing, and 
beyond, (Fig 1.2). Such observations help to explain why this agent, despite a short 
half life, may often be justifiably given to patients in a twice daily dosage, yet stil 
Maintain an extended therapeutic effect. 
Fig 1.2: 	 MEAN PLASMA AND SYNOVIAL FLUID CONCENTRATIONS 
JN 16 PATIENTS ON CHRONIC DICLOFENAC THERAPY FOR 
)1 HRS POST DOSE* 
By contrast, the oxicams have much longer t1t2 's and generaly take a week or 
longer to reach steady state plasma and synovial fluid concentrations folowing 
chronic administration at normal therapeutic dosage. Unlike the shorter tla 
NSAID's, synovial fluid concentrations increase with time in a manner similar to 
those in plasma with mean concentrations approximately 40% of plasma7, (as 
ilustrated below in Figure 1.3 for Piroxicam: 
Fig 1.3: PIROXICAM DISPOSITION FOLLOWING Ming ORALLY FOR 7 
DAYS 
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1.2 CHIRA NSAID'S 
Days 
A significant proportion of synthetic drugs, (including some of the NSAID's ) exhibit 
chirality108. In other words, they exist as optical / miror image isomers or 
Me° 
COOH 
Ibuprofen 
Ketoprofen 
Me 
Nap roxen 
Cl 
Pirprofen 
enantiomers. The 2-arylpropionic acids include some marketed and commonly 
prescribed NSAID's (Fig 1.4): 
Fig 1.4: 	 2- ARYI.PROPIONIC NSAID'S 
. denotes chiral centre 
The propionic acid side-chain possesses an asymmetric centre, the alpha carbon atom, 
so that two optical isomers (ie: enantiomers) exist. 
From a pharmacological viewpoint, the prostaglandin synthetase inhibiting efect of 
these NSAID's is atributable to the S(+) enantiomers79. Furthermore, these 
compounds undergo metabolic inversion from the R(-) enantiomer to the 
corresponding S(+) form by an unproven mechanism31. The reverse reaction has 
never been detected32. There appears to be considerable variability amongst the chiral 
NSAID's in terms of the extent of inversion. Ibuprofen, for example, has been 
demonstrated to undergo approximately 2/3 conversion of a dose of r(-) to s(+) 
7 
ibuprofen33 , whilst ketoprofen to a significantly lesser extent81 . Moreover, it has been 
claimed that the pharmacokinetic behaviour of the two enantiomers in humans may be 
different31,109 , so the stereoselective investigation of the pharmacokinetic parameters 
of these agents would appear to be of scientific and medical relevance. 
The disposition of the enantiomers has received little attention78 , as much of the earlier 
analytical methodology did not discriminate the individual optical isomers 71 . 
1.3 CHARACTERISTICS OF SYNOVIAL FLUID 
1.3.1 The Nature of Synovial Fluid 
Synovial fluid is a clear, pale yellow or straw coloured viscous liquid consisting of 
serum ultrafiltrate and mucopolysaccharide seeretions produced exclusively by the 
synovial membrane. This thin film of fluid between the joints, aside from offering 
mechanical protection against joint " wear and tear ", permits nutrient and metabolic 
waste exchange for articular cartilage. Numerous studiesl, many dating back to the 
early 1940's support the general concept that electrolytes and non-electrolytes are 
distributed in synovial fluid as a plasma dialysate to which hyaluronate (mucin) is 
added. However, it is of interest to note that Cl - and HCO3 - are present in synovial 
fluid in high concentrations relative to serum whilst Nat, K+, Ca2+ and Mg2+ are 
relatively lower2 . 
Water and small solutes (including the vast majority of anti-rheumatic drugs) move 
readily between synovial fluid and plasma via the synovial interstitium and are 
diffusion rate limited 12 . 
Hyaluronic acid ( a non sulphated polysaccharide composed of equimolar quantities of 
d-glucuronic acid/n-acetyl-d-glucosamine residues) represents about 0.3% of the 
composition of synovial fluidl. It is this substance in particular which is responsible 
for some of the unique properties of synovial fluid, including its viscosity 
characteristics. In vitro work by Ogston and Phelps3 demonstrated that the presence 
8 
of this physically large, asymmetric molecule can significantly obstruct the passage of 
some solutes. This concept enables one to gain an appreciation as to why larger 
molecules such as fibrinogen are excluded whilst smaller molecules are not. One may 
therefore be led to suspect that quantitative/qualitative variations in hyaluronate 
produced under varying rheumatic conditions could make significant contributions to 
the nature of synovial fluid. 
Transynovial exchange of plasma proteins on the other hand is significantly different 
from that of small solutes and is monodirectional into the joint space. Protein levels are 
always lower in synovial fluid compared to plasma. Typical total protein levels are 
around 18g/L4, however this may increase in trauma and rheumatoid states (see Table 
1.2). 
1.3.2 Protein Binding of NSAID's in Synovial Fluid 
1.3.2.1 Proteins in synovial fluid • 
As previously discussed, most of the NSALD's are acidic and bind principally to 
albumin. As such, drug levels in synovial fluid are usually a reflection upon the 
fluid's corresponding albumin concentration.Table 1.1 shows the commonly accepted 
values for protein binding of some commonly prescribed NSALD's. A close 
examination of the available data reveals that little emphasis has been placed upon 
measurement of the free or unbound levels of NSA1D's in blood(plasma,serum) at 
commonly used therapeutic dosages in clinical practice, let alone in synovial fluid. 
Presumably, this is due to the difficulties involved in accurate and reliable 
measurement of such low levels in the laboratory. 
The albumin concentration in synovial fluid, (whilst lower than the corresponding 
concentration in plasma ) can also vary dramatically under various pathological 
situations as Table 1.2 also illustrates. In addition, albumin concentrations tend to fall 
with age, resulting in higher free NSA1D fractions compared to younger patients 69 . 
9 
Appearance WBC Pt 
g/L 
Alb 
% 
Non Inf 
Efusion 
Nomial clear,yelow 0 200 18 63 
Trauma clear+ 1500 33 58 
D.J.D. clear-H- 600 30 57 
Non Inf.Inflam. 
Effusion(severe) 
R.A. turbid 15500 42 42 
Gout turbid 13500 49 70 
Non Infectious 
Inflam. 
Effusions(mild) 
S.L.E. clear/turbid < 2860 32 60 
Inflam.Effusions 
Infectious 
Acute Bacterial very turbid < 73000 44 33 
al al f 	 [HA] % % % 	 mg/100mL 
7 9 14 300 
8 12 16 170 
8 12 16 190 
1 14 25 90 
6 12 9 50 
6 15 15 180 
10 1 37 40 
7 
6 
6 
8 
3 
4 
Table 1.2: 	 5YNOVIAL FLUID ANALYSIS UNDER VARIOUS 
PATHOLOGICAL CONDITIONS° 
# 	 adapted from Cohenl 
< 	 decreased 
+ 	 occasionaly bloody 
++ occasionaly slightly turbid 
p 	 viscosity : ( 0 = normal, < = decreased ) 
DJD 
RA 
WBC 
HA 
Pt 
Alb 
degenerative joint disease 
rheumatoid arthritis 
white blood cel count 
hyaluronic acid 
total protein 
albumin 
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Whilst there can be up to a three fold increase in albumin concentration in the presence 
of inflammation, Balantyne and co-workers13 demonstrated lower synovial fluid 
albumin levels in patients with chronic inflammatory joint disease. They maintain this 
is principaly a result of increased albumin catabolism. Numerous atempts have been 
made to demonstrate a quantifiable difference between albumins in normal and 
rheumatoid patients, but with mixed success14 15, whilst others have atempted to 
demonstrate albumin drug binding inhibition via endogenous binding antagonists, 
such as free faty acith16. 
The albumin concentration in synovial fluid generaly ranges from 11-12g/L (normal 
subjects) through 17-20g/L (rheumatoid arthritis, trauma and degenerative joint 
disease) to over 30g/L (gouty arthritis). 
1.3.2.2 Binding in Synovial Fluid 
Unbound drug equilibrates between plasma and synovial fluid so that at steady state, 
the average concentrations of drug in each compartment are the same. As the albumin 
concentration in synovial fluid is lower than plasma, the binding is also lower. For an 
NSAlD with low hepatic extraction, this results in the folowing changes (Table 1.3): 
Table 1.3: 	 EFFECT OF  
Pharmacokinetic 	 Efect of Reduced Binding for: 
Parameter 	 Total Drug 	 Unbound Drug 
Clearance (Cl) 	 increased 	 unchanged 
Volume of Distribution (Vd) 	 increased 	 unchanged 
Half Life (4 r2) 	 unchanged 	 unchanged 
Plasma Concn. at steady state (Cs) 	 decreased 	 unchanged 
* adapted from Birket73 
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Bound to free ratios of drug concentration in the extravascular compartment are 
dependent upon a number of factors including the presence of other exogenous 
substances (including other drugs) and non specific tissue protein binding, which al 
have the potential to inhibit NSAID binding to albumin. These factors have received 
litle atention over the years12. 
1.3.2.3 Binding Sites 
The primary structure of Human Serum Albumin is now wel established17,18 and it 
has been demonstrated that many substances, (aside from NSAID's) bind with high 
affinity, including faty acids,bilirubin,tryptophan and numerous drugs. In addition, 
some NSAID's are capable of binding to multiple sites on albumin and with varying 
degrees of affinity48, (Table 1.4): 
Table 1.4: 	 1-1SA BINDING SITES OF SOME COMMON NSAID'S 
SITE 1 (WARFARIN SITE) 	 SITE 2 (DIAZEPAM SITE) 	 SITE 3 	 SITE 4 
Phenylbutazonc 	 Flurbiprofen (1)+ 	 Indomethaein 	 Tolmctin 
Sulphinpyrazone 	 Ibuprofen (1)4" 
Flurbiprofen (2)-4- 	 Indomethacin 
Indomethacin 	 Ketoprofen (1)4- 
Ketoprofen (2)4- 	 Naproxen 
Naproxcn 	 Mefenamic acid 
Salicylamidc 
Salicylazosalicylic acid 
Salicylosalicylic acid 
Adapted from Sjoholm19, Sudlowet a12° and Wanwiriolruk et a121. 
+ These substances can bind to multiple sites, [primary (1), secondary (2) ]. 
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Binding sites should not be perceived as preformed locations or zones on the protein 
surface, but more flexibly as areas of binding which are principaly determined by the 
bound drug itself and are able to be altered according to general thermodynamic 
principles. Energetic coupling between these binding sites may incite a ligand 
bound to one site to impair or improve the binding of a second ligand at another 
binding site. However, the pharmacological dosage of the currently available 
NSAID's is relatively smal so that plasma / synovial fluid concentrations never reach 
equimolar HSA concentrations.Essentialy therefore, only one site is active with very 
litle influence from secondary sites1 9. 
1.4 MEASUREMENT OF FREE / UNBOUND NSAID 
The direct methods of spectrophotometry, NMR, ESR and optical rotatory dispersion, 
whilst alowing measurement of rapid binding changes between drug molecules and 
proteins, are limited to special applications for which values are primarily relative and 
unsuitable for routine binding estimations. 
The indirect methods of equilibrium dialysis, ultrafiltration, ultracentrifugation, gel 
filtration and electrophoresis are generaly perceived as more adaptable methods. 
Complete separation of drug and protein is unnecessary as only a smal portion of 
protein - free solution need be colected in order to ascertain the free drug 
concentration in the original solution. Binding is indirectly calculated as: 
Cbound = 	 Ctotal " Cfree 	 Equation 1.1 
The use of one or more of these particular methods requires consideration of the 
physico - chemical properties of both the drug and the protein, (Table 1.5): 
13 
Table 1.5 COMPARISON OF INDIRECT METHODS FOR BINDING STUDIES* 
Equilibrium Dialysis 
Ultrafiltration 
Advantages 
•minimal disturbance to binding 
equilibrium. 
•suitable for high molecular wt. 
drugs. 
•relatively reliable method. 
•relatively insignificant changes 
in drug concentration. 
•suitable for high concentration 
protein solutions. 
•rapid method. 
Disadvantages 
•adsorption to membrane. 
•Donnan efect? 
•altered drug concentration, 
as determined by binding rate. 
•time consuming, especialy 
with high molecular wt. drugs. 
•eror increases with sieve efect 
in drugs with molecular wt.>300. 
•protein concentration increases 
during filtration. 
•adsorption to membrane material. 
•Donnan efect? 
Ultracentrifugation •minimal adsorption of drugs to 
centrifuge tubes. 
•drug sedimentation a problem with 
high molecular weight drugs. 
•relatively slow (12 - 15 hours). 
•complex technique, leads to 
increased variability. 
Gel Filtration •especialy suitable for drugs 
with high molecular wt. 
•can be less time consuming if 
preconditions known. 
•inaccurate for drugs with low 
protein afinity. 
•relatively large volumes of 
drug/protein required. 
•unsuitable for drugs strongly 
bound to gel. 
Electrophoresis 	 • simple qualitative and 	 • variable efect on binding 
quantitative estimations. 	 equilibria. 
•bufer/curent combinations often 
tricky and time consuming. 
# adapted from Kurz22 and Svensson74 
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1.5 GENERAL OBJECTIVES OF THIS STUDY 
The above examples highlight the relative importance of monitoring synovial fluid 
NSATD levels as an aid in characterising drug behaviour. An appreciation of the 
unbound drug level is particularly appropriate, as it has been wel established that it is 
free drug (the active species), which is in equilibrium between plasma and synovial 
fluid. Understandably, recent advances in techniques to determine free drug 
concentrations have lead to a substantial increase in the monitoring of this parameter in 
clinical practice68. 
The general objectives of this study were to examine the influence of endogenous and 
physical factors on this equilibrium, and to establish the possible significance (if any), 
that fluctuations in their serum concentrations may have on NSAID disposition. 
The research was undertaken in two distinct parts: 
a) The development and establishment of procedures to separate the free 
NSAID fraction in synovial fluid and assay the extremely low levels 
of unbound drug therein. 
and 	 b) The use of these procedures to examine some of the endogenous and 
physical factors which affect the protein binding and 
consequential free fraction of selected NSAID's in both synovial fluid 
and plasma. 
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CHAPTER 2 
PROTEIN BINDING DETERMINATIONS 
2.1 THE AMICON ULTRAFILTRATION SYSTEM 
For the folowing studies, the Amicon MPS-1 ultrafiltration apparatus was employed, 
(Fig 2.1): 
Fig 2.1 	 111EADILCOMILS.:11/LTRAEILIBATION.DEME 
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The device rapidly and efficiently separates free/unbound drug from protein bound 
microsolute in small volumes (0.15-1.0mL). Convenient separation of a portion of 
unbound drug is achieved by convective filtration of unbound material through the 
semi - permeable YMT ultrafiltration membrane. Extremely high YMT membrane 
permselectivity is demonstrated by retention of > 99.9% serum protein and < 5% 
1-thyroxine99. Centrifugation (1000-2000g) provides sufficient driving force for the 
samples of synovial fluid and albumin used. Ultrafiltrate (containing unbound drug) 
collects in the filtrate cup and as the total drug volume is unchanged, unbound drug 
concentration remains unchanged on both sides of the membrane. This has been amply 
demonstrated by Whitlam and Brown 24 . Using a similar device, they showed that 
during the ultrafiltration procedure, the concentration remained undisturbed and that 
the fraction of fluid filtered is therefore unimportant. 
2.2 MEASUREMENT OF UNBOUND NSAID LEVEL 
2.2.1 Ultrafiltration in Conjunction with Radiolabelling 
NSAID's are very highly protein bound. For example, at normal therapeutic 
concentrations of piroxicam ( synovial fluid concentration of approx. 211g/mL), this 
NSAID is about 99% bound7,67. This relates to a free / unbound fraction of 1% or 
less. A procedure for measuring free levels of the order of 2Ong/tnL or lower, with 
consistency and precision is required. The use of radiolabelled NSAlD (usually 3H or 
14C), offers an exquisitely suitable solution to this problem. Synovial fluid may be 
spiked with the radio-labelled NSALD and a portion of the free fraction collected by 
ultrafiltration. Scintillation counting of samples before and after filtration allow for the 
determination of free fraction at these low levels. This method is relatively fast, 
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convenient and in many instances, sufficiently sensitive to determine unbound drug 
concentrations in normal clinical practice. 
2.2.2 Ultrafiltration in Conjunction with Chromatography 
However, in many instances, the specific activity of the radiolabelled NSAID is too 
low to enable measurement of the free fraction at normal therapeutic levels. In fact, in 
many instances when working at normal therapeutic concentrations of the NSAID in 
question, the operator may have difficulty in resolving drug radioactivity from 
background radiation. In these instances, radiolabelling is inappropriate and 
alternative procedures need to be considered.These include HPLC, GC or GC/MS 
assays. With some notable exceptions, HPLC assays are generally unsuitable for 
measuring free levels of such highly bound drugs due to sensitivity limitations°. GC 
assays, though often involving lengthy and sometimes complex derivatizations, 
usually offer enhanced sensitivity compared to other methods. Futhermore, use of 
GC/MS techniques enable an even greater opportunity for further sensitivity and have 
the advantage of permitting confirmation of structure of derivatized drug. 
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CHAPTER 3 
METHODS 
3.1 SYNOVIAL FLUID  
3.1.1 Collection Procedure 
Following receipt of Ethics Committee approval from the institutions concerned, 
samples of synovial fluid were collected from patients in accordance with protocol 
(see Appendix 1). It is usual to collect fluid from effusions into the knee, as this is 
the most accessible joint. Synovial fluid aspirations for this study were only 
performed as part of their normal therapeutic treatment regimen. In many instances, 
aspiration serves to provide a substantial therapeutic effect for these patients - some 
by relieving pressure in the joint, others by permitting the instillation of medication 
(eg: antibiotics) in certain infected joint spaces. Following intracutaneous injection 
of local anesthetic (lignocaine or procaine 1%), the aspiration needle is progressively 
passed through the synovial membrane and into the joint cavity whereupon the fluid 
is withdrawn into the syringe. All fluids used in these studies, unless otherwise 
stated, were collected via aspiration of the knee joint. 
3.1.2 Sample Classification 
In accordance with guidelines set by Schumacher66, this analysis commenced 
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literally the moment the specimen appeared in the syringe following joint aspiration. 
The colour was noted and particular attention given to the presence or absence of 
blood, (due to trauma of the surrounding tissue structures). In addition to the colour 
of the fluid, note was made of its visual clarity - clear, turbid or sometimes grossly 
purulent. Routine WBC counts were performed in most instances as an objective 
measure of inflammation. Although the WBC count is a non specific diagnostic 
procedure, it is an important laboratory aid in distinguishing different types of 
synovial fluid - at least within broad groupings (Table 1.2). For WBC analysis, 
synovial fluid was placed in a glass sample vial containing an anticoagulant (EDTA 
or heparin) and analysed* within 2 hours of joint aspiration. A portion of this 
sample was also used to establish albumin and total protein concentrations. 
3.1.3 Protein Determinations* 
3.1.3.1 Albumin and Total Protein 
Albumin was determined by colourimetric determination with bromocresol green 75 
using an automatic stat random analyser (ASTRA®) 76. The usable range for serum / 
synovial fluid albumin determination on the ASTRA® is 10-70g/L with an 
imprecision of 3.0%. 
Total protein was determined by the classical biuret method75 on the ASTRA® by 
injection of the sample into the alkaline copper reagent and measurement of the rate 
of change of absorption (wavelength = 545nm) at 11 sec by a microprocessor - 
linked optical system. The usable range is 30-120g/L for plasma or synovial fluid 
with an imprecision of 3.0%. 
* By courteous assistance of the Repatriation General Hospital, Hobart, Tasmania. 
3.1.3.2 Electrophoresis 
The synovial fluid must be "fresh" (less than 24 hours since collection) as even a 
small decrease in dispersion of its colloidal components can create undesirable 
"tailing" across the strips due to coarsely dispersed protein. Following collection, 
the synovial fluid was subjected to centrifugation at 2500g for 40 minutes at 37 0C, 
and a Silt portion of the supernatant transferred to a glass slide. Cellulose acetate 
electrophoretic strips (Gellman Sciences Inc, Arbor, Michigan, USA), were 
saturated in tris barbital buffer (Gellman Sciences) for 15 minutes and then removed 
and blotted of excess liquid. 11_11_, of the clarified synovial fluid was applied to a 
marked position on the first quartile segment of the strips via a fine, twin wire 
applicator(Gellman Sciences). The strip was immediately suspended between the 
two electrode - containing buffer cells of the electrophoresis tank (Gellman 
Sciences), and the entire tank sealed to minimise evaporation from the surface of the 
strip. The electrodes from each cell in the tank were connected to a Vokam SAE 
2761 constant voltage power supply (Shandon Sci, London, England), and a 
voltage of 150V maintained for 90 minutes*. This allowed a current (equating to 
approximately 1.5mV) to flow per strip. The strip was then removed from the tank 
and placed in a 0.2% w/v ponceau S dye solution (Gellman Sciences) for 10 
minutes. The strip was then removed, rinsed repeatedly in 10% v/v acetic acid 
solution (BDH, Port Fairy, Vic, Australia - analytical reagent grade) to remove 
excess dye,and then dried in an air oven at 70°C for 30 minutes. Dried strips were 
soaked in Whitemor Oil (Gurr's, London, England) prior to analysis on an ACD-18 
*The albumin "front" may be readily checked or qualified by the addition of bromophenol blue to 
the original protein solution prior to electrophoresis. 
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Automatic Computing Densitometer (Gellman Sciences), at a wavelength of 525nm. 
3.1.4 Practical Considerations 
During the initial investigation of the characteristics of synovial fluid, there was 
concern that formation of a mucin clot may hinder subsequent binding studies 
(perhaps by altering albumin concentration). To investigate this possibility, the 
initial synovial fluid samples collected were analysed for their respective albumin 
concentrations at 2 hours and again after 36 hours storage, (by which time a clot 
had formed). 
3.1.5 Storage 
3.1.5.1 General 
All synovial fluid samples were transferred to glass tapered tubes, centrifuged at 
1000g for 3 minutes (as soon as practically possible following collection), decanted, 
dead space in the containers flushed with a stream of nitrogen, stoppered and stored 
at 4°C until required. 
3.1.5. Stability Studies Using Piroxicam 
lmL aliquots of blank synovial fluid were transferred to glass tubes and the pH 
measured (Beckman Model 12 pH/ISE - c/- Activon Sci, Thornleigh, NSW, 
Australia). Samples were then spiked with 214 radiolabelled 3H piroxicam stock 
solution and the free or unbound fraction (F e) calculated in accordance with 
procedure 3.2.2. The procedure was performed initially, and after 36 hours storage 
at 4°C. 
3.2 PIROXICAM FREE FRACTION 
3.2.1 Radiolabelled Piroxicam 
3.2.1.1 Background 
Protein binding studies of piroxicam in synovial fluid and Human Serum Albumin 
(HSA) were greatly facilitated by the availability of radiolabelled piroxicam. 
Radioactive 3H Piroxicam was a generous gift from Pfizer Ltd (West Ryde, NSW, 
Australia). 
3.2.1.2 Purity 
The radiochemical purity (>90%) was verified at 6 monthly intervals by thin layer 
chromatography using the solvent mixture - chloroform : ethyl acetate : acetic acid : 
water (60:38:1.5:0.5). The specific activity was 29.98 gCi/mg. 
3.2.1.3 Stock Solution 
A radiolabelled 3H piroxicam solution ( lmg/mL in methanol) was prepared monthly 
and stored at 4°C. 
3.2.1.3.1 Assay of Stock Solution 
Freshly prepared stock solutions were verified by HPLC. Whilst numerous assays 
for this drug have been published 50-52, an assay following guidelines by Owen 46 
was chosen due to its extreme simplicity and speed. 
Stock solutions (prepared monthly) were verified by this method, and where 
necessary, adjusted to the required concentration (1mg/mL) with methanol. 
3.2.1.3.2 Instrumentation 
The HPLC system consisted of a Waters M45 solvent delivery system (Waters & 
Associates, Milford, MA, USA), which delivered the mobile phase at a flow rate of 
lmL/min to a Waters C18 pondapak column (steel - 300 x 3.9 mm ID, lOilm 
average particle size) fitted with a guard column (23 x 3.9 mm II)) packed with 
Waters Pondapak C 18/Corasilo, thence to a Waters model 441 fixed wavelength 
UV absorbance detector set at 254nm. Data were recorded on a LDC/Milton Roy 
C1-10 Integrator and SEK printer/plotter (LDC / Milton Roy Co, Clare, Ireland). 
The mobile phase [ acetonitrile : 0.03% phosphoric acid (pH 2.5) - 45:55 ] was 
filtered and degassed under reduced pressure before use. 
3.2.1.3.3 Procedure 
A standard curve was prepared by serial dilution of piroxicam (Pfizer Pty Ltd) with 
methanol, to produce a range of concentrations around the expected concentration of 
radiolabelled stock solution. 1(4tL of p-toluic acid (Sigma, St Louis, MO, USA) 
solution (l[tg/mL) was added as an internal standard. After vortex mixing for 10s, 
2011L of each sample was injected into the HPLC system. 
3.2.2 Ultrafiltration Procedure 
The binding of piroxicam to synovial fluid proteins was measured using 
ultrafiltration, facilitated by the Amicon MPS-1 micropartition system using YMT 
ultrafiltration membranes, (Chapter 2). 
A known quantity of radiolabeled 3H piroxicam stock solution (1mg/mL) was 
added to lmL of synovial fluid or albumin solution in a glass vial. The vial was then 
capped, inverted three times to facilitate mixing and incubated at 37°C for 5 min. A 
1004, aliquot was transferred to a glass scintilation vial (Packard Instrument Co, 
Downers Grove, Il, USA) and 5mL liquid scintilation fluid added (Insta-Gel : 
Packard Instrument Co). The mixture was counted by liquid scintilation 
spectrometry (LKB Walac - Rack 1215 Beta 2). The remainder of the incubated 
mixture was transferred to an Amicon MPS-1 unit (that had previously been warmed 
to 37°C) and placed in a smal swinging bucket rotor centrifuge (Jouan CT1000 - 
Jouan SA-BP, St Nazaire, Ce'dex, France) prewarmed to 37°C. The sample was 
centrifuged at 1500g for 20 min to produce approximately 2001AL of ultrafiltrate. A 
1001xL portion of this ultrafiltrate was analysed by liquid scintilation spectrometry 
as above. Successive channel ratio readings were similar over the range of 
concentrations used ( coeff.var. 1.8%, (n=20)) and obviated the need for 
correction due to quenching. Disintegrations per minute (dpm) were corrected for 
background noise and the fraction of unbound piroxicam (Fe) calculated as: 
dpm ultrafiltrate 
Fu 	 Equation 3.1 
dpm prefiltrate 
After use, the Amicon MP, S-1 unit was disassembled, filter and colection cup 
discarded and the remaining components rinsed in hot tap water, soaked overnight in 
Decone, then rinsed in tap water, followed by distilled water and then dried in an air 
oven at 37°C. 
3.2.2.1 Reproducibility 
The precision of the uhrafiltration procedure was determined in freshly prepared 
HSA (fraction V - CSL, Melbourne, Australia) 30g/L in water at a piroxicam 
concentration of 2[1g/mL. 
3.3 IBUPROFEN / KETOPROFEN FREE FRACTION 
3.3.1 Ketoprofen HPLC Enantiomeric Assay 
3.3.1.1 Chemicals and Reagents 
Standard stock solutions (21.tg/mL) of racemic ketoprofen (May and Baker, 
Melbourne, Australia) were prepared in methanol and stored at 4°C. The 1 - 
leucinamide (Sigma, St Louis, MO, USA) derivatizing reagent was prepared fresh 
weekly. All solvents were HPLC grade (Waters & Associates, Melbourne, 
Australia). 
3.3.1.2 Instrumentation 
The instrumentation was a modification of that used by Foster and Jamali41 . The 
HPLC system in the current studies consisted of a Waters 6000A solvent delivery 
system (Waters & Associates,Milford,MA,USA) and a Waters model 450 UV 
variable wavelength spectrophotometer. At ambient temperature, a Waters 
Novapak C18 Reversed Phase Column (3.9mm x 15cm - steel) fitted with a guard 
column (23 x 3.9 mm ID) packed with Pondapak C 18/Corasile (Waters) was 
utilised throughout. The mobile phase 0.06M potassium dihydrogen phosphate : 
acetonitrile : triethylamine (64:36:0.02) was filtered, degassed under reduced 
pressure and then pumped at a flow rate of lmL/min. The absorbance of the eluent 
was measured at 275nm and recorded on a dual-channel Omniscribe recorder 
(Houston Instruments, Austin, Texas, USA) tracking at 0.25cm/min. 
3.3.1.3 Sample Preparation 
A 0.5mL sample of "drug free" synovial fluid was spiked with a known 
amount of r,s - ketoprofen then acidified with 10011L of 0.6M sulphuric acid, and 
the mixture extracted with 3mL 5% isopropyl alcohol in isooctane (after vortex 
mixing for 30s and centrifuging at 1500g for 5 min). The organic layer was 
transferred to a clean glass tube and evaporated to dryness under a gentle stream of 
nitrogen. The residue was re-constituted in 1000, of 50mM triethylamine in 
acetonitrile. To this mixture, at 30s intervals were added 5011L of 60mM 
ethylchloroformate in acetonitrile and 5011L of a mixture of 1M 1 - leucinamide 
hydrochloride and 1M triethylamine in methanol. After 2 min, 504 of water was 
added and 40pL of this solution injected into the HPLC system. 
3.3.2 Ibuprofen/Ketoprofen Enantiomeric GC/MS Assays 
3.3.2.1 Chemicals and Reagents 
Samples of r (-) , s (+) and r,s- ibuprofen were the generous gift of The Boots 
Company (Boots, Nottingham UK). Standard stock solutions of ibuprofen 
(1mg/mL) were prepared in methanol and stored at 4°C. 
A stock solution of r,s-ketoprofen (Sigma, St Louis, MO, USA) 11.1g/mL was 
prepared in methanol and stored at 4°C. 
1,1'-carbonyldiimidazole (CDI) was purchased from Aldrich (Steinheim, West 
Germany). Dexamphetamine Sulphate was a gift from the Department of 
Community Services and Health (Hobart, Tasmania, Australia). All solvents were 
HPLC grade (Waters and Associates) and glass distilled prior to use. Water was 
deionised and glass distilled. All non-disposable glassware was washed with 
Pyroneg, rinsed with tap water, soaked overnight in Decon®, then rinsed with 
distilled water before drying in an air oven over silica gel. 
3.3.2.2 Optical Purity of Dexamphetamine 
The purity of dexamphetamine sulphate was estimated by optical rotation to be 
approximately 90%, (the 10% discrepancy attributable to contamination with its 
optical counterpart, I - amphetamine). On this basis, derivatization with ibuprofen 
{R (-) and S( +) ), will produce four diastereomers ( Rd, R1, Si, & Sd) - Fig 6.3; 
resolvable as two chromatographic peaks. A correction factor for this impurity can 
be made (via simultaneous equations) in subsequent quantitation of drug 
enantiomers. 
3.3.2.3 Preparation of Stock Solutions 
Standard solutions of CDI (1014/mL) were prepared fresh daily in chloroform. 
Dexamphetamine sulphate (equivalent to 50014 free base per mL) was 
prepared in water and stored at 4°C - stock solution A.  
A stock solution of dexamphetamine in methanol (stock solution B) was prepared 
as follows: 10mL of dexamphetamine sulphate aqueous stock solution was basified 
to pH 11 by the addition of 10Opt 2M sodium hydroxide and extracted with 25mL 
diethyl ether. The organic phase was carefully evaporated to near dryness under a 
gentle stream of nitrogen gas. The residue was reconstituted with 10mL methanol, 
stoppered and stored at 4°C. 
3.3.2.4 Preparation of Test Samples 
3.3.2.4.1 Using CDI 
lmL Sorensens Phosphate Buffer pH7.4 was spiked with racemic ibuprofen, 
acidified to pH1 with 100111. 5M hydrochloric acid and then extracted with 4iriL 
toluene. Meanwhile,1001.iL of dexamphetamine stock solution A was basified with 
1004, 1M sodium hydroxide and extracted with 4mL toluene. The two extracts 
were combined in a 10mL reaction vial (Alltech,Deerfield,ILUSA), evaporated to 
dryness and reconstituted with lmL of CDI stock solution. The tube was screw 
capped and sealed under an atmosphere of nitrogen gas and then heated for 2 hours 
at 85°C in a GC oven (Pye 104: Pye,Cambridge,UK). After cooling to room 
temperature, the reaction mixture was washed with lmL 1M hydrochloric acid and 
the organic phase dried over magnesium sulphate and evaporated to dryness. The 
residue was reconstituted with 1001.IL toluene and 14L of this solution was then 
injected into the GC/MS system. 
3.3.2.4.2 Using Ethylchloroformate 
A 200pL portion of ibuprofen stock solution (containing 2014 ibuprofen) was 
transferred to a tapered glass centrifuge tube and carefully evaporated to dryness 
under a gentle stream of nitrogen gas. The residue was reconstituted with 100p1 . of 
50rnM triethylamine in acetonitrile. To this mixture at 30s intervals were added 
50pL of 60mM ethylchloroformate in acetonitrile and 50pL of dexamphetamine 
stock solution B. After 1 min, 0.5mL of chilled water was added followed by 3mL 
dichloromethane. The mixture was vortexed for 30s, centrifuged, ( Jouan CT 1000 - 
Jouan SA-BP, St Nazaire,Ce -dex,France) for 5min at 1500g and 4°C. The organic 
layer was transferred to a clean tapered glass tube and carefully evaporated to 
dryness under a stream of nitrogen. The residue was then reconstituted in 20pL 
toluene and 1pL of this sample was injected into the GC/MS system. 
3.3.2.5 Instrumentation 
The GC/MS system comprised a Hewlett Packard 5890 GC coupled with an 
HP5970 mass selective detector and an HP59970A data system. A 25 x 0.32mm 
internal diameter fused silica capillary column with a cross-linked methyl silicone 
bonded stationary phase of film thickness 0.17p. (HP-1 ) was used with helium 
carrier gas at a linear velocity of 55 cm/sec at 50°C. The oven temperature was 
programmed from 50°C (for lmin) to 220°C at 30°C/min and from 220°C to 
270°C at 100C/min. The injector temperature was 250°C and the transfer line 
temperature was 290°C. Injection (1pL) was by means of a Hewlett Packard 
7673A autosampler. Structures of the diastereoisomeric amides were to be 
confirmed by electron impact MS. Ful scan reference spectra of the amphetamine 
derivatives of both enantiomerso were used to select appropriate ions for 
quantitative selected ion monitoring (SIM) during analytical runs. 
3.3.2.6 Internal Standards 
3.3.2.6.1 0 - Toluic Acid 
11.ig samples (from a l lag/mL stock solution) of o-toluic acid (Sigma, St Louis, 
MO, USA) were prepared, derivatized (3.3.2.4.2) and chromatographed (3.3.2.5): 
Sample 1: 
Sample 2: 
200p_L water spiked with ltg r,s-ibuprofen and then 
extracted as above. lpg o-toluic acid was then added (as an 
internal standard) and the mixture then derivatize,d and 
chromatographed. 
200pL water spiked with Itg o-toluic acid and then 
extracted as above. ltg r,s-ibuprofen was then added (as 
an internal standard) and the mixture then derivatized and 
chromatographed. 
Sample 3: 	 200pL water spiked with lpg o-toluic acid and 1 lig 
r,s-ibuprofen and then extracted, derivatized and 
chromatographed. 
Sample 4: 	 ltg o-toluic acid and ltg r,s-ibuprofen mixed 
together,evaporated to near dryness and then derivatized and 
chromatographod. 
Sample 5: 	 Repeat of sample 4. 
Sample 6: 	 ltg o-toluic acid,ltg r,s-ibuprofen and 3mL of the 
extraction solvent were mixed,evaporated to near dryness 
and then derivatized and chromatographed. 
Peak area ratios of o-toluic acid to r,s-ibuprofen were then calculated. 
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3.3.2.6.2 Naproxen 
A li_tg/mL stock solution of Naproxen (Syntex,Sydney,Australia) in methanol was 
prepared and stored at 4°C. A lmL portion of this stock solution was carefully 
evaporated to near dryness under a gentle stream of nitrogen and then derivatized 
(3.3.2.4.2) and chromatographed (3.3.2.5) in accordance with fore mentioned 
procedures. 
3.3.2.7 Effect of Reaction Time on Derivatization 
To ascertain optimum times for this assay, 4Ong s-ibuprofen and l[tg p-toluic acid 
from their respective stock solutions were derivatized together according to 
3.3.2.4.2, except a series of samples were prepared by varying the reaction time 
from 0.25 to 10 minutes. 
3.3.2.8 Effect of Varied Amount of Dexamphetamine Reagent 
Samples of 4Ong s-ibuprofen and 11.tg p-toluic acid were prepared (3.3.2.4.2), 
except the amount of dexamphetamine derivatizing reagent was varied between 20 -
300[1.L. 
3.3.2.9 Extraction Solvent 
0.1% iso-propyl alcohol in toluene (Waters and Associates), were both HPLC grade 
and freshly glass distilled prior to use. 
3.3.2.10 Contamination 
"Blank" (or NSAID free) samples were run in conjunction with all GC/MS sample 
runs, to monitor for accidentally introduced contaminants in the assay system. 
3.3.2.11 Preparation of Biological Samples: 
All biological samples were prepared according to procedure depicted in Fig 3.1: 
Fig 3.1: 	 PERIVATIZATION OF BIOLOGICAL SAMPLES 
200pL synovial fluid / albumin solution 
Add 	 1001.11. naproxen(lpg/mL) as internal std. 
20p_L 5M HCI (acidified to pH I) 
3mL isopropyl alcohol 0.1% in n-hexane Ivortex 1min centrifuge 1500g, 5min, 4°C 
organic layer 
evaporate to near dryness 
under stream N2 gas 
residue 
Add: 	 100pL 50mM triethylamine in acetonitrile 
30s: 	 501.1L 60mM ethylchloroformate in acetonitrile 
30s: 	 504, dexamphetarnine reagent (equiv. 2mg/mL free base in methanol) 
60s: 	 0.5mL water(chiled) + 3mL dichloromethane 
vortex 30s, centrifuge 3min, 4°C 
organic layer 
Add 	 evaporate to near dryness under N2 
201.1.L toluene to residue 
vortex 30s 
Inject lpL GC/MS 
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3.3.2.12 Preparation of Standard Curves 
200gL samples of "blank" albumin (Fraction V - CSL, Melbourne, Australia) 
18g/L in Sorensen's phosphate buffer pH 7.4, were spiked with predetermined 
amounts of s(+) and r(-) ibuprofen or ketoprofen, and derivatized(3.3.2.11) and 
chromatographed (3.3.2.5) as before. 
Calibration curves were prepared by plotting the ratio of peak area of the drug 
enantiomer to the peak area of the internal standard versus concentration of the 
drug.Standards were prepared fortnightly and stored at 4°C. 
3.3.2.13 Assay Reproducibility and Precision 
lmL samples of Sorensens phosphate buffer pH 7.4, were spiked with 
pre-determined amounts of s(+)- and r(-)- ibuprofen and ultrafiltrated using the 
Amicon MPS-1 device (Chapter 2). 2001.1L aliquots of ultrafiltrate were derivatized 
(3.3.2.11) and chromatographed (3.3.2.5). 
3.3.2.14 Sample Stability 
Two sample sets of ibuprofen standard solutions (3.3.2.12), were re-
chromatographed 48 hours after derivatization. 
3.3.2.15 Ultrafiltration Procedure 
lmL samples of synovial fluid / albumin solutions were ultrafiltrated using the 
Amicon MPS-1 ultrafiltration device. The ultrafiltrate was derivatized (3.3.2.11) and 
chromatographed (3.3.2.5) and the free fraction calculated (Equation 3.1). 
3.4 METHODS FOR NSAID BINDING STUDIES 
3.4.1 Effect of NSAID Concentration 
3.4.1.1 Piroxicam 
Radiolabelled 3H piroxicam at a range of concentrations between 1 and 614,./mL was 
incubated at 37°C for 5 min in the presence of HSA* (Fraction V - CSL, 
Melbourne, Australia) 18g/L in 0.067M Sorensen's phosphate buffer pH7.4, and 
ultrafiltrated using the Amicon MPS-1 device (3.2.2). 
3.4.1.2 Ibuprofen 
Experiments were conducted using racemic ibuprofen concentrations expected 
within the normal therapeutic range in synovial fluid (1-20[1g/mL) 39 . lmL portions 
of blank HSA (Fraction V - CSL, Melbourne, Australia) 18g/L in 0.067M 
Sorensen's phosphate buffer were transferred to glass vials and spiked with pre - 
determined amounts of r(-)- and s(+)- ibuprofen stock solutions (1mg/mL in 
methanol), to produce a range of pseudo-racemic ibuprofen concentrations within 
the desired range. The mixtures were inverted to facilitate mixing, incubated in an 
air oven at 37°C for 5 min, then transferred to the Arnicon MPS-1 devices and 
subject to ultrafiltration (3.3.2.15). 2001.IL portions of ultrafiltrate were derivatized 
(3.3.2.11) and chromatographed (3.3.2.5) as previously outlined. 
* HSA = Human Serum Albumin 
3.4.2 Effect of Protein Concentration 
3.4.2.1 Piroxicam 
Radiolabelled 3H piroxicam ( at a concentration of 214/mL ) was incubated for 5min 
at 37°C in 0.067M Sorensen's phosphate buffer pH7.4, in the presence of 
HSA(Fraction V - CSL, Melbourne, Australia) within the concentration range 12 to 
30g/L. The incubation mixture was subject to ultrafiltration via the Amicon MPS-1 
device (3.2.2). The experiment was repeated with two samples of synovial fluid 
(previously assayed (3.1.3) and found to contain 24g/L and 21g/L albumin 
respectively) which were serially diluted with phosphate buffer. 
3.4.2.2 Ibuprofen 
A series of lmL synovial fluid / albumin solutions were prepared by dilution with 
pre-determined quantities of 0.067M Sorensen's phosphate buffer pH 7.40. The lmL 
samples were then spiked with 2014 r,s-ibuprofen, incubated for 5 minutes at 37°C, 
ultrafiltrated (3.3.2.15), derivatized (3.3.2.11) and chromatographed (3.3.2.5). 
3.4.3 Chiral NSAID Enantiomer Ratio 
The effect of varying this ratio by increasing the proportion of s(+)-ibuprofen was 
investigated, commencing with a pseudo-racemic ibuprofen concentration of 
14s/mL, (ie: 614/mL of r(-)-ibuprofen plus 6p.g/mL of s(+)-ibuprofen 
enantiomers). ltriL HSA (Fraction V - CSL) 18g/L in 0.067M isotonic phosphate 
buffer pH 7.37 was spiked with 121.4 r,s-ibuprofen. A series of similar samples were 
prepared, maintaining r - ibuprofen at 61.tg/mL but with incremental quantities of 
s-ibuprofen up to 40gg/rnL. The samples were incubated for 5 minutes at 37°C, 
ultrafiltrated (3.3.2.15), derivatized (3.3.2.11) and chromatographed (3.3.2.5). 
3.4.4 Effects of Fatty Acids 
3.4.4.1 Binding in "Stripped" Albumin 
lmL samples of HSA ( Fraction V - Sigma, St Louis, Mo, USA) 18g/L (that had 
previously been stripped of fatty acids by the method of Chen49), in 0.067M 
Sorensen's phosphate buffer pH7.4, were transferred to glass vials. Pre-determined 
quantities of r(-) - and s(+) - ibuprofen stock solutions (1mg/mL in methanol) were 
added to these solutions in the range 2 - 20pg/mL for each enantiomer. The samples 
were incubated for 5 minutes at 37°C, ultrafiltrated (3.3.2.15), derivatized (3.3.2.11), 
chromatographed (3.3.2.5), and the free fractions subsequently calculated. 
3.4.4.2 Addition of Fatty Acid 
lmL samples of 'stripped' albumin solutions were transferred to glass vials. 
Pre-determined quantities of sodium oleate (1mg/mL) stock solution were added to 
these tubes to produce a range of albumin solutions from 0.5mM to 1mM with respect 
to oleic acid. Varying amounts of r(-)- or s(+)- ibuprofen stock solutions (1mg/mL in 
methanol) were added to these solutions in the range 2 - 201.1g/mL for each 
enantiomer. The samples were then incubated, ultrafiltrated, derivatized and 
chromatographed according to procedure 3.4.4.1. 
3.4.5 Effect of pH 
For each sample, 18mg HSA (fraction V - CSL) was reconstituted in lmL of 
Sorensen's phosphate buffer solution, which had been carefully adjusted to the 
required pH77 . After gentle mixing, 21.tg of radiolabelled 3H piroxicam stock solution 
(1mg/mL in methanol) was added, mixed by inversion and pH of the resultant solution 
reconfirmed, (Beckman model 12 pH/ISE, Activon Sci.). The samples were incubated 
for 5 minutes at 37°C, ultrafiltrated (3.3.2.15), derivatized (3.3.2.11) and 
chromatographed (3.3.2.5). 
3.5 PATA INTERPRETATION 
Piroxicam and ibuprofen binding data (3.4.1) were compared to the following 
mathematical models for goodness of fit, using FUNFIT®, an interactive program for 
non-linear regressionm° : 
Scatchard Mode188 : 
Klotz Mode185 : 
Larsen Mode182 : 
Larsen / Klotz Mode182 : 
Trigonometric Mode186 : 
Exponential Mode186 : 
r=(n i ki C/1 + C) + (n2k2C / 1 + k2 C) 
r= (kiC + 2kik2C2 ) /( 1 + kiC+ kik2C2 ) 
r=b1ln(b2C+1) 
r=k1ln[2(k1-2k2)C+1]/2(k1-k2) 
B =a1 arctan ( a2 T ) 
B=b1(1-exp(-b2T)) 
where: r is the average number of bound drug molecules per molecule of albumin; C is the free 
drug concentration; k 1 and k2 are the association / binding constants; n 1 ,n2 
are the number of class binding sites; al and a2 and b 1 and b2 are the parameters of the 
models as determined from the experimental data; B is the concentration of bound drug; T is 
the concentration of total drug. 
CHAPTER 4 
RESULTS: ASSAY OF UNBOUND DRUG 
4.1 5YNOVIAL FLUID SAMPLES 
4.1.1 Sample Stability 
The albumin concentrations of three samples of synovial fluid were calculated 
immediately after joint aspiration and after 36 hours storage at 4°C, (Table 4.1): 
Table 4.1: 	 EFFECT OF CLOT FORMATION ON ALBUMIN  
CONCENTRATION IN SYNOVIAL FLUID 
Patient No. Patient I.D. [Albumin] 0-2hrs 
(g/1-) 
[Albumin] 36hrs 
(g/L) 
1 AA 17.2 17.0 
2 GY 20.7 21.0 
3 CC 18.0 17.6 
There was an insignificant (< 3%) alteration to albumin concentration folowing clot 
formation. For sampling purposes it was therefore considered reasonable that when a 
large clot formed in subsequent samples, fluid would be withdrawn from the 
colection vessel using the tip of a micropipete positioned between the clot and the 
wal of the container so as to minimise volumetric eror. 
4.1.2 Elect rophoresis 
A sample of non-inflammatory synovial fluid (white cel count <100) was subjected to 
the procedure outlined in 3.1.3.2, and the individual protein fractions resolved, (Fig 
4.1): 
Fig 4.1: 	 Electrophoretic strip showing component proteins* in synovial fluid 
from a rheumatoid arthritic patient (non-inflammatory). 
7 	 R 	 a2 	 al 	 atrril 
(1.7g/L) 	 (2.2g,/L) 	 (3.8g/L) (4.2g/L) 	 (1 8g/L) 
* Total Protein (method 3.1.3.1) = 30g/L 
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4.1.3 Sample Storage 
The multiplicity of tests conducted on each synovial fluid sample were foreseen to be 
very time consuming events and therefore stability tests under varying environmental 
conditions were deemed necessary. It was considered feasable that denaturation of a 
major binding component during storage could influence free NSAID fraction in the 
samples. To investigate this possibility, the appearance,pH and protein binding 
characteristics of numerous samples were investigated whilst being stored at 4°C in 
stoppered glass tubes with minimal dead space. The data are ilustrated in table 4.2. 
Table 4.2: 	 EFFECT OF STORAGE ON SYNOVIAL FLUID 
Sample 	 Day 0 	 Day 2 	 Day 10 	 Day 30 
pH° 	 Fu* 	 pH° Fu* 	 pH° Fu* 	 pH° Fu* 
1 7.51 2.11 7.62 2.15 7.67 2.15 7.95 2.25 
2 7.56 2.40 7.61 2.47 7.76 2.21 
3 7.45 2.62 7.50 2.38 7.55 2.40 
Fu = fraction unbound of piroxicam: 
* coeficient of variation = 9.8% 
° coeficient of variation = 0.3% 
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4.2 PIROXICAM 
4.2.1 HPLC Assay 
4.2.1.1 Identification 
The internal standard (p-toluic acid), and piroxicam were eluted at 5.89 and 7.73 
minutes respectively, (Fig 4.2): 
4 
LS. 
L. 
0 	 4 	 8 	 12 16 20 
Time (minutes) 
Fig 4.2 	 HPLC profile of piroxicam in methanol. Peaks: Ls. = internal 
standard; p = piroxicam. 
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4.2.1.2 Standard Curve 
A standard curve was prepared by ploting the ratio of peak height of piroxicam to 
the peak height of the internal standard versus concentration of piroxicam (Fig 4.3): 
Fig 4.3: 	 FIROXICAM STANDARD CURVE 
10 	 20 	 30 
Piroxicam Concn. (gg/mL) 
The precision of the assay has been previously assessed46, and the coeficient of 
variation for piroxicam at 51.ig/mL calculated to be 4.1%. 
4.2.2 Reproducibility of Ultrafiltration Procedure 
At a piroxicam concentration of 21.ig/mL, the free/unbound fraction (Fe) was calculated 
in five samples, (Table 4.3): 
Table 4.3 	 FIROXICAM FREE FRACTION BY 13.TRAFILTRATION 
Sample Fu 
1 0.0125 
2 0.0101 
3 0.0102 
4 0.0123 
5 0.0109 
Mean (± SD) 0.0122 (0.0011) 
Coeficient of variation = 9.8% 
Recovery of radiolabeled 3H piroxicam from the Amicon MPS-1 device was 
determined in 4 samples of HSA (fraction V -CSL) 18g/L in isotonic phosphate 
bufer which had been spiked with radiolabeled drug. The mean recovery 
(2.55i_ig/mL piroxicam) was 92.7% (SD 8.1%). The diference may be atributed to 
binding associated with the Amicon device and / or YMT membrane. According to 
previous studies by Whitlam and Brown24, this is unlikely to be significant. 
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4.3 J1311PROFEN 
4.3.1 GC/MS Assay Using Dexamphetamine / CDI 
With reference to retention times and mass spectra undertaken by previous 
researcherso, the enantiomers in their reaction sequence were either undetected or 
unresolved. A lj.tL portion of the sample was transferred to a direct insertion probe on 
a VG 7070F mass spectrometer for confirmation of structure by electron impact MS. 
The spectra did not show the characteristic 1M-117]+ fragment which is characteristic 
of the amphetamine portion of the molecular ion, nor did it show other characteristic 
fragments,(nVz 91,119,118) previously investigated°. As there was no evidence of 
formation of amphetamine derivatives based on the mass spectra subsequently 
obtained, it was hypothesised that CDI was not acting as the intended coupling agent 
in the derivatization reaction. A 14, sample of freshly prepared CDI reagent was 
transferred to the insertion probe and mass spectra obtained, (Fig 4.4). 
Fig 4.4: MASS SPECTRA OF FRESHLY PREPARED CDT REAGENT 
f): f; 	 G-9- JUN- E 9 
GML,SLAIMElh: 	 0,31. 
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4.3.2 GC/MS Assay Using Dexamphetamine / Ethylchloroformate 
4.3.2.1 Identification of Enantiomers 
Two peaks were resolved at 9.82 and 9.89 min, and mass spectra published by 
previous investigatorso confirmed these peaks to be the required derivatives. SIM of 
m/z 232 gave the cleanest trace, with freedom from interfering peaks. Fig 4.5 depicts a 
chromatographic trace originating from a 250ng test sample of ibuprofen in methanol: 
Fig 4.5: GC TRACE OF IBUPROFEN DIASTEREOMERS 
Ion 232.02 amu. from V3:0CISR329.0 
Peaks: 1 = s(+)- ibuprofen; 2 = r(-)- ibuprofen diastereomers 
4.3.2.2 Selection of Internal Standard 
4.3.2.2.1 	 p - toluic acid 
The amphetamine derivative of p-toluic acid was confirmed to elute at 8.61min, with 
SIM of m/z 119 providing the best chromatographic trace. However, there were 
numerous interfering peaks which occured in conjunction with al p-toluic acid 
samples available in these laboratories, and an alternative was therefore investigated. 
4.3.2.2.2 o - toluic acid 
SIM of m/z 162 provided the 'cleanest' chromatographic trace. Inconsistencies with 
repetitive derivatizations of some samples were investigated (method 3.3.2.6.1) and 
summarised by Table 4.4: 
Table 4.4: 	 o-TOLUIC ACID / R.S-TRUPROFEN ASSAY 
	
Sample 	 Peak Area Ratio 
Number 	 (o-toluic acid : r,s- ibuprofen) 
1 1.26 
2 0.15 
3 0.26 
4 0.19 
5 0.16 
6 0.13 
2.0E4 - 
c1 .5E4- 
  
  
    
Ion 185.00 amu. from V3:0C19R32R.D 1 
10 	 11 	 12 
Time (min.) 
d3 
4.3.2.2.3 Naproxen 
Using SIM m/z 185, two peaks were eluted at 12.68 and 12.82 min, with mass 
spectra characteristic of the amphetamine derivatives of naproxen. SIM of m/z 185 
provided the best chromatographic trace, free from interfering peaks, (Fig 4.6): 
Fig 4.6: 	 GC & MASS SPECTRA OF NAPROXEN DIASTEREOMERS 
I) 
Rverage 
1.8E6 
1.6E6 
1.4E6 
1.2E6 
1.0E6 
of 12.720 
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to 12.800 min. from V3:NRPROX2.D 
85 
256 347 
8.0E5 
6.0E5 91 CE 4.0E5 1,4 	1 
2.0E5 2,75 
100 200 300 Mass/Charge 
A = mass spectra of naproxen-dexamphetamine diastereomers. 
B = gc/ms chromatographic resolution of 50Ong/mL naproxen(1); peak(2) is a minor 
contaminant resulting from naproxen and/or dexamphetamlne 
con tam ination40. 
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4.3.2.3 Reaction Time 
The optimum time interval for the coupling reaction was assessed (method 3.3.2.7), 
and represented by Fig 4.7: 
Fig 4.7: 	 EFFECT OF REACTION TIME 
3.0 — 
•• • 	 • 	 • 
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4.3.2.4 Derivatizing Reagent 
The optimum quantity of derivatizing reagent was assessed (method 3.3.2.8), and 
represented by Fig 4.8: 
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Fig 4.8: EFFECT OF AMOUNT DEXAMPHETAMINE REAGENT ADDED 
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4.3.2.5 Standard Curves 
The calibration curves (Fig 4.9) were linear over the concentration range 
10-200ng/mL. The minimum quantifiable concentration was 2.5ng/mL, using the 
ultrafiltration procedure (3.3.2.15). In efect, this equated to a 25pcg4LL on column 
injection and verged on the limits of detectability of the equipment. Lines of best fit 
through the origin were calculated by linear regression. The corelation coeficient R, 
was generaly > 0.99 for a 5 point standard curve. 
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Fig 4.9: 	 CALIBRATION CURVES FOR S(+) AND R(-) IBUPROFEN 
1: s - IBUPROFEN 
2:r - IBUPROFEN 
4.3.2.6 Reproducibility and Precision 
The precision of the assay for the ibuprofen enantiomers at a high and low 
concentration is given in Table 4.5: 
Table 4.5: 	 PRECISION OF THE IBUPROFEN ASSAY 
Drug Theoretical 
(ng/mL) 
Number of 
Determinations 
Experimental 
Mean ± SD (ng/mL) 
CV* 
(%) 
s(+) Ibuprofen 50 5 42.38 4.57 10.8 
150 5 136.2 5.70 4.2 
r(-) Ibuprofen 50 5 45.7 3.38 7.4 
150 5 136.3 6.05 4.4 
* CV = coeficient of variation 
4.3.2.7 Stability 
Two sets of sample derivatives were re-chromatographed (3.3.2.5) after 48 hours at 
4°C, in order to assess stability, (Table 4.6): 
Table 4.6: 	 SAMPLE STABILITY OVER 4RHR PERIOD 
Derivative 	 Theoretical 	 Experimental 	 Change 
(ng/m1.,) 	 (ng/mL) 	 (%) 
Ohr 48hrs 
s(+) ibuprofen 
r(-) ibuprofen 
20 	 19.0 19.0 	 0 
50 	 45.2 40.5 	 10.4 (-) 
100 	 95.2 95.2 	 0 
150 	 140.5 128.6 	 8.5 (-) 
200 	 247.6 216.7 	 12.5 (-) 
20 	 20.4 20.4 	 0 
50 	 46.9 42.9 	 8.5 (-) 
100 	 93.9 95.9 	 2.1 (+) 
150 	 136.7 126.5 	 7.5 (-) 
200 	 234.7 210.2 	 10.4 (-) 
4.4 KETOPROFEN 
4.4.1 HPLC Assay 
Fig 4.10 depicts a chromatogram of synovial fluid spiked with 200ng/mL racemic 
ketoprofen, ( ie: 10Ong/mL of each enantiomer, assuming the racemic drug to be an 
equal mix of each enantiomer): 
Time (minutes) 
0 	 4 	 8 	 12 16 20 24 
Fig 4.10: HPLC profile of blank synovial fluid spiked with 10Ong/mL of 
racemic ketoprofen. Peaks: 1 = r(-)- ketoprofen; 2 = s(+)- 
ketoprofen. 
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4.4.2 GC/MS Assay Using Dexamphetamine / Ethylchloroformate 
4.4.2.1 Identification of Enantiomers 
Two peaks at 13.08 and 13.19min for s(+) and r(-) ketoprofen respectively, were 
eluted. Mass spectra confirmed these to be the required peaks. SIM of rniz 280 
provided a clean trace,free from interfering peaks, (Fig 4.11): 
Fig 4.11: 	 GC & MASS SPECTRA FOR KETOPROFEN ENANTIOMERS 
A 
A:mass spectra of s(+)- ketoprofen diastereomer. 
B:mass spectra of r(-)- ketoprofen diastereomer. 
C:gc/ms(SIM m/z 280)resolution of s(+)- ketoprofen(1); r(-)- ketoprofen(2) dlastereomers. 
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4.4.2.2 Standard Curves 
The calibration curves for ketoprofen enantiomers(5-25ng/mL) are ilustrated in Fig 
4.12: 
Fig 4.12: CALIBRATION CURVES FOR S(+) AND R(-1 KETOPROFEN 
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CHAPTER 5 
RESULTS: NSAID BINDING STUDIES 
5.1 	 NS AID CONCENTRATION 
5.1.1 Piroxicam 
The free fraction(Fu) of unbound piroxicam in HSA solution (18g/L) over a range of 
piroxicam concentrations (1-6n/mL), is represented by Fig 5.1: 
Fig 5.1: 
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The experiment was repeated using blank synovial fluid (previously assayed (3.1.3) 
and found to contain 24g/L albumin), and the folowing results obtained (Fig 5.2): 
Fig 5.2: 	 Eli vs iPiroxicaml - SYNOVIAL FLUID 
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At al total piroxicam concentrations, the free fraction in synovial fluid was greater 
than in HSA solution. 
5.1.2 Ibuprofen 
The free fraction of ibuprofen enantiomers in HSA solution (18g/L) was investigated 
over a range of enantiomer concentrations, (Fig5.3): 
Fig 5.3: 	 BINDING OF IBUPROFEN ENANTIOMERS TO HSA (1iG/L1 
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The experiment was repeated in a sample of synovial fluid {previously assayed 
(3.1.3), and found to contain 18g/L albumin) - Fig 5.4: 
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5.1.3 Binding / Association Constants 
The preceeding data (5.1) were fited to the fore mentioned mathematical models (3.5). 
Examples of plots and fited curves are ilustrated in Fig 5.5, whilst 
binding/association constants for the fited data are shown in Table 5.1: 
Fig 5.5: 	 EXAMPLES OF BINDING PLOTS*I1SED TO CALCI ILATE 
BINDING / ASSOCIATION CONSTANTS 
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Table 5.1: 	 lilgatici jeARAMEIER/SEMAIES# CHARACTERIZING THE 
JNTERACTION OF IBI IPROFEN AND PIROXICAM WITH 
.11I MIN IN SYNOVIAL FI.11ID AND BUFFER SOLUTIONS. 
MODEL PIROXICAM 	 r-IBUPROFEN 	 s-IBUPROFEN 
H SA SF° HSA SF + FAF° HSA SF + FAF° 
Scatchard 
k1 (10-6M-1) 9.81(86) 0.75(41) 70.8(28) 12.5(93) 42.5(58) 20.8(10) 5.9(18) 51.7(48) 
ni 0.05(82) 0.15(47) 0.19(20) 0.34(101) 0.29(40) 0.15(6) 0.22(16) 0.28(30) 
k2 (10-6M-1 ) 10.8(35) 7.62(56) 213(63) 143(270) 187(705) 148(2) 374(114) 99.2(62) 
n2 127(29) 2.0(1000) 12.9(148) 30.7(513) 33.7(745) 8.99(18) 7.46(94) 70.9(6) 
Klotz 
k1 (10-6M1) 0.35(7) 0.07(7) 3.86(14) 3.15(8) 4.26(21) 0.98(9) 0.98(9) 4.55(22) 
k2 (104M-1) 0.04(*) 8.12(*) 50.3(*) 5.67(*) 27.2(*) 0.004(*) 0.004(*) 2.32(*) 
Larsen 
b1 (10-3) 2.42(198) 2.19(137) 2.96(983) 5.17(480) 3.23(395) 3.07(2000) 3.33(625) 37.7(1168) 
b2 134(195) 28.4(137) 995(980) 441(479) 763(377) 203(2000) 216(606) 69.4(1157) 
Larsen / Klotz 
k1 (10-6M-1) 0.35(7) 0.07(19) 3.77(21) 3.04(16) 3.87(20) 0.79(40) 0.95(19) 4.13(23) 
k2 (104M-1) 0.035(*) 3.07(*) 103(*) 2.30(*) 5.92(*) 99.3(*) 0.003(*) 2.17(*) 
Trigonometric 
al (10-3) 3.14(0.05) 2.63(0.2) 3.14(0.01) 3.14(0.01) 3.15(0.02) 3.20(0.04) 3.21(0.04) 3.15(0.01) 
a2 (10-4) 3.15(0.05) 3.60(0.2) 3.18(0.01) 3.18(0.01) 3.17(0.02) 3.11(0.04) 3.10(0.04) 3.18(0.01) 
Exponential 
b1 (10-3) 3.14(0.03) 2.62(0.2) 3.13(0.01) 2.80(0.004) 3.15(0.02) 3.18(0.09) 3.22(0.07) 3.15(0.06) 
b2(10) 3.15(0.03) 3.61(0.2) 3.19(0.01) 3.57(0.003) 3.17(0.03) 3.13(0.02) 3.09(0.001) 3.17(0.03) 
= value ± coeficient of variation; * = (> 106 ); HSA = Human Serum Albumin (18g/L solution); SF = Synovial 
Fluid : ° = 24g/L HSA ; = 18g/L HSA ; ° FAF = Faty Acid Free Albumin Solution(18g/L) 
62 
Fr
ee 
Fr
act
io
n (
Fu
) 
c) 	
P 	
P 	
P 	
P 
CD 
	
C) 
	
CD 
	
C) 
	
C:a
 
0 
	
C> 
	
,_.
 	
....•
 
ON 
	
00 
	
41'  
a 	
1 	
• 	
1 	
1 	
1 	
• 	
1 
0 
0 
CI 
cp CD "ZS CD CD et 0—t h=1 CD 1:1) FD ra.
 C„ cra cp '1=1 CD CD $1) 9 Ft> 0 0 E. Cra 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
crT
 
:9-g 2tA 
 ut uon!2 
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Fig 5.7: FIROXICAM - FL vs [ALBUMIN] IN SYNOVIAL FLUID 
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5.2.2 Ibuprofen 
The free fraction of ibuprofen enantiomers 10p.g/mL r(-) and 10pg/mL s(+)) in 
HSA solutions of varied concentration are represented in Fig 5.8: 
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5.3 CHIRAL NSAID ENANTIOMER RATIO 
The effect on free fraction (F.), of increasing the concentration of the s(+) enantiomer 
of ibuprofen relative to a fixed concentration of the r(-) enantiomer was examined in 
HSA solutions (18g/L) - Table 5.2: 
Table 5.2: 	 EFFECT OF VARIATION TO IBUPROFEN 
ENANTIOMER RATIO  
Sample 	 Enantiomer Concn. 	 Fu* 
No 	 (ig/mL) 
R-IBU S-IBU R-IBU S-113U 
1 6 6 0.0012 0.0034 
2 6 9 0.0014 0.0040 
3 6 12 0.0017 0.0054 
4 6 L5 0.0053 0.0175 
5 6 20 0.0034 0.0204 
6 6 33 0.0048 0.0253 
7 6 40 0.0084 0.0293 
* coeficient of variation: R-IBU = 7.4%; S-IBU = 10.8% 
5.4 FATTY ACIDS 
5.4.1 Ibuprofen Binding in Stripped Albumin 
The binding of ibuprofen enantiomers (2-20gg/mL) in "faty acid - stripped" HSA 
solutions (18g/L) was examined, (Fig 5.9): 
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Fig 5.9: 	 BINDING OF IBUPROFEN FNANTIOMERS IN FATTY 
ACID - FREE HSA (18,/L) 
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5.4.2 Addition of Fatty Acid 
The efect on free drug fraction (Fe), of adding a faty acid (oleic acid) to "stripped" 
HSA solutions (18g/L) in the presence of various concentrations of ibuprofen 
enantiomers and oleic acid concentrations, was examined, (Table 5.3): 
Table 5.3: 	 EFFECT OF FATTY ACID ON IBUPROFEN 
FNANTIOMER BINDING 
Enantiomer Conc. 	 Free Fraction (Fu*) 
(14,/mL) Sodium Oleate Added - 	(Molar ratio of Oleic Acid to albumin) 
2:1 	 3:1 4:1 
R-IBU 	 S-IBU 	 R-IBU S-IBU R-IBU S-IBU 
2 0.00048 	 0.00072 	 0.00050 0.00120 0.00140 0.00950 
5 0.00033 	 0.00062 	 0.00051 0.00150 0.00110 0.00940 
10 0.00034 	 0.00071 	 0.00062 0.00220 0.00120 0.01300 
15 0.00044 	 0.00120 	 0.00062 0.00250 0.00190 0.01500 
20 0.00073 	 0.00260 	 0.00082 0.00340 0.00200 0.02400 
* coeficient of variation: R-IBU = 7.4%; S-1BU = 10.8% 
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5.5 pH 
The influence of pH on free fraction (F.), of piroxicam (21.1.g/mL) was examined over 
a pH range typicaly found in pathological synovial fluid - Table 5.4: 
Table 5.4: 	 EFFECT OF pH ON PIROXICAM BINDING IN HSA (18G/I.1 
pH 	 Fu Determinations 	 Mean 
7.05 
7.27 
7.37 
7.41 
7.45 
7.48 
7.49 
0.0132, 
0.0121, 
0.0116, 
0.0092, 
0.0090, 
0.0092, 
0.0101, 
0.0125 
0.0125 
0.0141 
0.0128, 
0.0100 
0.0100 
0.0105 
0.0114 
0.0129 
0.0123 
0.0129 
0.0111 
0.0095 
0.0096 
0.0103 
mean 0.0112 ± 0.0015 S.D. 
CHAPTER 6 
DISCUSSION 
6.1 $YNOVIAL FLUID  
6.1.1 Practical Considerations 
Normal synovial fluid has a high viscosity and when drawn with a glass pipete 
tends to form a tenacious string several centimetres in length before finaly breaking. 
This property alone presents difficulties in volumetric analysis and in some 
instances, this may necessitate densitometric measurement involving weighing. 
However, pathological fluids generaly have reduced viscosity because of dilution 
and/or enzymatic atack on the hyaluronic acid molecule25 and therefore tend to pour 
readily from a pipete. Normal synovial fluid does not clot as fibrinogen and other 
cloting factors are absent. However, clots do occur in pathologic fluids and their 
size is roughly proportional to the severity of the inflammationl. Mucin clot 
formation* occurs spontaneously within several days of storage and can vary from a 
tight ropey mass in a clear solution (good mucin) to smal soft masses in a turbid 
solution (poor mucin). Generaly, the more inflamed the joint, the worse the mucinl. 
* 	 This may be induced in the laboratory immediately folowing sample colection by mixing 
with aqueous acetic acid solution. This "mucin test" has been used as a descriptive qualitative test 
to give an indication as to the physical state of the hyaluronic addl. 
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Whilst protein determinations (3.1.3) are not specifically diagnostic of a specific 
articular disease, one can be reasonably certain that a fluid is not normal when the 
total proteins exceed 25giL and that moderately severe inflammation is present when 
total proteins exceed 45g/L. 
6.1.2 Electrophoresis Study 
This procedure is commonly used in clinical laboratories for the separation of 
proteins found in serum. In aqueous medium, proteins form aggregates of charged 
molecules (micelles), and upon application of an electric field, the individual protein 
molecules move towards the electrode of opposite charge. For the purposes of this 
investigation, cellulose acetate electrophoresis was employed as this provided a 
reliable and convenient medium upon which to separate the principle proteins in 
synovial fluid. Proteins in synovial fluid dissolve in the buffer on the cellulose 
acetate strip and the applied current across the strip allows the individual protein 
molecules to begin migration along the matrix of cellulose fibre "channels" towards 
the anode. The rates at which the various proteins do this will depend upon their 
respective mobilities75 . 
Schmid and MacNair29 used electrophoresis to examine the nature of the protein in 
synovial fluid. They compared synovial fluid and corresponding plasma from 
rheumatoid patients and noted the similarity between proteins in both fluids. In the 
current studies, the viscosity and high levels of mucopolysaccharides in synovial 
fluid made resolution of component proteins difficult2,75 . However, this latest 
investigation confirmed the pattern of proteins in synovial fluids used in the current 
binding studies was comparable to plasma (and in agreement with previous 
researchers29). 
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6.1.3 Stability and Storage 
The pH of stored samples increased slightly 2.1%) at day 10 to 5_ 5.8% after 30 
days. This is presumably due to the loss of carbon dioxide. Normal synovial fluid is 
reported2 as having a similar pH to serum of 7.31-7.64, though there are reports of 
higher values of mean 7•77 1 • 
There was an insignificant amount of variation with respect to the free fraction (Fe) 
of stored samples. The variation was within the experimental limits of the procedure 
and considered unlikely to be of practical importance. 
6.2 piRoxicAm  
6.2.1 Radiolabelled Piroxicam 
6.2.1.1 Background 
These studies were made possible by the ready availability of radiolabelled 3H 
piroxicam (Fig 6.1): . 
Fig 6.1: 	 FIROXICAM 
* 3H radiolabel 
6.2.1.2 Stability 
The stock solution was protected from light at al times, as reports of similar 
experiments using radiolabeled tenoxicam solutions exposed to sunlight resulted in 
minor degradation of the drug and subsequent erors in free fraction determination61. 
6.2.2 Precision and Reproducibility of Ultrafiltration Procedure 
The precision of the assay has been previously assessed46, and the coeficient of 
variation for piroxicam at 51.tg/mL calculated to be 4.1%. The mean recovery 
(2.5514/mL piroxicam) was 92.7% (SD 8.1%). The diference may be atributed to 
binding associated with the Amicon device and / or YMT membrane. According to 
previous studies by Whitlam and Brown24, this is unlikely to be significant. 
The radiolabeled drug alowed for rapid and convenient determination of piroxicam 
free fractions in synovial fluid and albumin solutions (using the Amicon MPS-1 
ultrafiltration device), with a coeficient of variation of 9.8%. 
7'3 
CH3 
> CH — CH2 e
H 
C — Cr CH3 
COOH CI.13 
R(-) - ibuprofen 
6.3 IBUPROFEN 
6.3.1 Background 
Ibuprofen [2-(4-isobutylphenyl) propionic acid] has a propionic acid side - chain 
with an asymmetric centre, the alpha carbon atom, (Fig 6.2): 
Fig 6.2: 	 IBUPROFEN ENANTIOMERS 
CH3 
CH3 
CH— CH2 
,CH3 
—CH 
COOH 
S(-) - ibuprofen 
Two optical isomers (enantiomers) therefore exist. 
6.3.2 Radiolabeled Ibuprofen 
Radiolabeled enantiomers of ibuprofen of suitable specific activity would 
have greatly facilitated the development of a suitable assay procedure. 
Unfortunately, the difficulty, expense and time involved in producing suitable 
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radiolabelled materia1 63.64 made this procedure impractical. It was decided that a 
suitably sensitive chromatographic assay procedure was the most logical alternative. 
Cox and co-workers" on the other hand, opted to persist with the preparation of 
radiolabelled enantiomers in their ongoing endevours to examine plasma and tissue 
protein binding affinities of this drug. 
6.3.3 Sensitivity Considerations 
The ultrafiltration procedure using the Amicon MPS-1 device provided the 
ultrafiltrate from which subsequent chromatographic analysis was undertaken. As 
supplies of drug free synovial fluid from volunteers used in this research (Appendix 
1) were infrequent and understandibly small in volume (typically less than 15mL), a 
maximum of only lmL of fluid could be allocated to each Amicon MPS-1 device. 
Of this, only 20011L could be realised as collectable ultrafiltrate. Therefore, the 
amount of free drug available for chromatographic assay was reduced by a factor of 
5 from the outset. Alternative, slower procedures such as equilibrium dialysis, 
which allow collection of larger amounts of free drug, were considered unsuitable 
for later binding experiments with competing ligands and other binding 
modifiers48,24 . It was envisaged that an assay capable of detecting 2ng/mL and 
5ng/mL of ketoprofen and ibuprofen enantiomers respectively was required. This 
meant that existing assays had to be improved substantially in terms of sensitivity if 
this technique were to be used. 
6.3.4 Previous Assay Attempts 
Generally speaking, gas chromatographic methods for separation of NSAID 
enantiomers are difficult as the isomers have the same physical properties. 
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There have been numerous atempts at quantification of racaemic ibuprofen in 
biological fluids36, yet relatively few atempts at resolving the enantiomers. The 
limited number of published enantiomeric assays involve either the use of opticaly 
active stationary phases36,57, or more commonly, derivatization to diastereomers by 
reaction with an opticaly active reagent37-4°. The later methods are usualy time 
consuming procedures, often involving complex derivatization reactions and 
lengthy incubation periods. This is often necessary, however, as detection and 
quantification may be improved by selection of chiral resolving agents which confer 
enhanced detector sensitivity on the resulting diastereomers. Table 6.1 ilustrates 
some examples of earlier enantiomeric NSAID assays. 
Table 6.1 	 EXAN1P1,ES OF SOME ENANTIOMERIC NSAID ASSAYS 
Author 	 NSAID(s) 	 Instrument". 	 Lower 	 Additional 
Limits 	 Drawbacks 
Augerinos37 ibuprofen HPLC 0.5p.g/mL 
Salustio56 ketoprofen ft 0.2p.g/mL 
Geislinger36 It II 0.1p.g/mL 
Fostee41 ketoprofen 5Ong/mL 
Goto58 naproxen lOng/mL 
Lee39 ibuprofen HPLC 0.5tg/mL 
Kaiser38 ibuprofen GC 0.51g/mL 
Singh° ibuprofen ,t 75ng/mL 
ketoprofen ft n/a 
naproxen t, n/a 
2hr. reaction time. 
complex derivatizing reagent 
synthesis; expensive; slow. 
lhr. reaction time. 
2hr reaction time; unstable 
derivatizing agent. 
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Ideally, a relatively simple and straightforward HPLC assay (of sufficient sensitivity 
to enable detection of free levels of ibuprofen enantiomers in synovial fluid), was 
required' 11  In addition, it would be convenient if such an assay could be modified to 
allow measurement of the enantiomers of other chiral NSAID's such as ketoprofen. 
Royer et a143 developed an HPLC assay for ketoprofen in plasma using UV detection 
and applied it to the study of its plasma protein binding, using an equilibrium dialysis 
system. Whilst the method was rapid and relatively sensitive (2ng/mL), it made no 
attempt at resolving the individual enantiomers. Meanwhile, Bjorkman42 and Foster 
and Jamali41 reported plasma assays for the enantiomers of indoprofen and ketoprofen 
respectively. Their methods involved extraction of unchanged drug, conversion to a 
mixed anhydride with ethylchloroformate, derivatisation with 1 - leucinamide, 
extraction of the formed diastereomers with an organic solvent, and subsequent 
evaporation and injection into the HPLC system. The method developed by these two 
research groups was appealing, from a speed and simplicity point of view as 
compared to the fore mentioned GC procedures. The latter work was viewed as an 
ideal starting point for the development of an assay of sufficient sensitivity for the 
intended investigation of the unbound enantiomers of ibuprofen and ketoprofen in 
synovial fluid. As later discussed (6.4.1), the Foster and Jamali HPLC assay41 did not 
provide sufficient sensitivity for the intended investigations with ketoprofen. Whilst it 
was initially intended to further pursue this issue with ketoprofen, the unavailability of 
ketoprofen enantiomers compared to the ready availability of ibuprofen enantiomers 
(courtesy of The Boots Company, Nottingham, U.K.), caused the research to 
orientate towards the development of a suitably sensitive enantiomeric ibuprofen 
assay (which in turn could be adapted for ketoprofen at a later date). As all practical 
alternatives for a suitably sensitive HPLC assay had been pursued, attention was 
focused on the development of a suitably sensitive GC/MS assay. 
6.3.5 GC/MS Enantiomerie Assays 
6.3.5.1 Background 
GC assays are generally more time consuming than HPLC assays, yet often have 
the inherent advantage of greater sensitivity. Ideally, a GC assay of high sensitivity 
using mass spectrometry for enhanced sensitivity with a rapid, relatively simple 
work-up, (typical of many HPLC assays) was required. Singh and co-workerso 
developed an enantiomeric assay for several NSAID's (including ibuprofen and 
ketoprofen) using optically active amphetamine to form the diastereomers and then 
separated them using capillary gas chromatography with nitrogen - phosphorous 
detection. They found dexamphetamine to be a preferred alternative to alpha - 
methylbenzylamine as used by earlier workerso. Furthermore, they used 
1,1'-carbonyldiimidazole (CDI) as their coupling reagent instead of thionyl chloride 
as it has been observed that" the hydroxylated metabolites of ibuprofen are readily 
'dehydrated and hydrohalogenated by this agent 14". Their work was viewed as the 
next logical step in the current work, for the development of a suitably sensitive 
assay. The ready availability of a suitable GC/MS system for this work was seen as 
a means of not only re-establishing their assay, but also as a possible means of 
enhancing sensitivity by the use of selected ion monitoring. 
6.3.5.2 GC/MS Assay Using Dexamphetamine CDI 
The spectra of the CDI reagent (Fig 4.4), obtained in the course of this assay was 
characteristic of imidazole and included m/z 36; characteristic of Ha (presumably 
from chloroform in the reagent). When solid CDI was transferred directly to the 
probe, a mass spectra characteristic of CDI was observed, whilst the tri/z 36 ion 
78 
fragment was absent. Data thus far supported the theory that HC1 impurity in the 
chloroform was facilitating the hydrolysis of CDI and rendering it unsuitable for 
derivatization work. 
A lmg/mL solution of CDI in chloroform was analysed by infra red spectroscopy, 
and from the IR spectra, there appeared to be an abundance of irniciazole and an 
insignificant amount of CDI present. From this, it appeared that CDI had 
spontaneously decomposed to its imidazole counterpart. This is consistent with the 
findings of Kaiser and co-workers 38 , who conducted stability studies on CDI 
reagent and found substantial degredation to imidazole albeit after 48 hours. 
Several other batches of chloroform available in this laboratory were tested, yet 
these all failed to provide a reagent of sufficient stability. As further samples of CDI 
were not readily attainable, it was decided to abandon this reagent in favour of 
another. Furthermore, the lengthy incubation period for derivatization was viewed 
as a significant disadvantage. It was therefore decided to explore alternative 
coupling agents with expectations of a more rapid and less finical assay procedure. 
6.3.5.3 GC/MS Assay Using Dexamphetamine / Ethylchloroformate 
The ketoprofen HPLC assay (3.3.1) established, provided a rapid derivatization 
procedure for the enantiomeric leucinamide derivatives by using ethylchloroformate 
as the coupling reagent. As mass spectra for the amphetamine derivatives of 
ibuprofen have previously been determined40 , it seemed logical to attempt the 
derivatization with dexamphetamine as above, but using ethylchloroformate as the 
coupling reagent. The reaction is a two step procedure; ie: the formation of a mixed 
anhydride of ibuprofen and ethylchloroformate and its subsequent conversion to an 
amide by reaction with dexamphetamine to produce the required diastereomers. 
The expected products are illustrated in Fig 6.3: 
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6.3.5.3.1 Derivatization Reaction Time 
Ethylchloroformate is a commonly used reagent for amide formation in peptide 
synthesis42, but not commonly used in this capacity in analytical chemistry. When 
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used in conjunction with 1-leucinamide (as in the current HPLC assay), the coupling 
reaction is complete in less than 3 min41,42,62 . In the amphetamine derivatization, 
there was negligible variation in peak area ratio after 60 seconds, (Fig 4.7). A 
reaction time of 60 seconds was therefore settled upon. 
6.3.5.3.2 Dexanzphetamine Reagent Quantity 
A large excess of dexamphetamine theoretically remains after biological sample 
derivatization40. In the current studies, a volume of 504, (equivalent to 100lig free 
base) was settled upon (based on the negligible variation in yield with increasing 
volume of reagent used - Fig 4.8). This was twice the amount used by Singh°. 
6.3.5.3.3 Extraction Solvent 
A number of extraction solvents for ibuprofen in synovial fluid were considered. A • 
study by Lee and co-workers 39 compared numerous extraction solvents from earlier 
NSAID assays and concluded that 0.1% isopropyl alcohol (IPA) in n-hexane was 
the most suitable for their studies with ibuprofen. It allowed rapid and reasonable 
recovery (85% or better for both enantiomers in the concentration ranges examined) 
of drug with minimal interfering peaks.This solvent system was therefore used in 
these studies. 
6.3.5.3.4 Contamination 
Contamination of both chemicals and reagents are common, ongoing problems with 
any assay working in the picogram range of detection. The development of this drug 
assay was severely hampered by such problems in its early stages. Blank (ibuprofen 
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free) derivatizations in both synovial fluid and water repeatedly produced peaks, 
consistent with a small amount of ibuprofen contamination. 10mL samples of all 
solvents involved in the assay were evaporated to near dryness and derivatized and 
chromatogrammed in the usual manner. However,this failed to locate the offending 
agent(s),It was not until a new batch of ethylchloroformate and triethylamine were 
obtained that the problem was resolved. "Blank" samples were assayed during all 
subsequent runs to monitor this problem. 
6.3.5.3.5 Internal Standard 
P-toluic acid was used in an earlier HPLC assay" which had been developed to 
quantify numerous NSAID's in plasma and subsequently used in the early stages of 
development of this assay. However, it was considered far from ideal as supplies of 
p-toluic acid available at these laboratories were contaminated with unknown 
material, and a clean chromatographic trace could not be readily obtained. A supply 
of o-toluic acid was readily available which did not cause this problem. Whilst this 
agent appeared superficially suitable, there were problems, not only in terms of 
repeatability of results, but also in obtaining a linear correlation with respect to the 
development of a standard curve. It was hypothesised that problems were occurring 
in the extraction procedure and/or the evaporation steps. The data (Table 4.4), 
demonstrate not only the large variation in extraction efficiency of ibuprofen as 
compared to o-toluic acid (samples 1 & 2), but also the variability in derivatized 
o-toluic acid of both extracted (1,2& 3) and non extracted (4,5 & 6), samples. Rapid 
loss of o-toluic acid during the evaporation step is consistent with this data, and also 
in agreement with guidelines developed by Grob and Muller47 . They demonstrated 
rapid and significant losses (10-15%) of solute material (up to C 21 ) when 
co-evaporated with solvents under a stream of nitrogen gas. In addition, they 
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demonstrated that losses may be dramatic when a sample is allowed to evaporate to 
complete dryness. Naproxen, being a larger molecule and more akin to ibuprofen 
than o-toluic acid was considered a potentially more suitable alternative. The second 
peak in the trace (Fig 4.6) was attributable to I-amphetamine contamination in the 
dexamphetamine derivatization reagent and possibly r-naproxen contamination in the 
naproxen. For the purpose of this assay however, this was to be of no consequence, 
as total peak areas of both peaks were considered in subsequent calculations. 
6.3.5.3.6 Standard Curves 
The calibration curves were linear over the concentration range 10-200 ng/mL. The 
minimum quantifiable concentration was 2.5ng/mL, in conjunction with the 
ultrafiltration procedure (3.3.2.15), and was markedly more sensitive than previous 
assays (Table 6.1). 
6.3.5.3.7 Assay Reproducibility and Precision 
Using the ultrafiltration procedure (3.3.2.15), the coefficient of variation for 
determination of ibuprofen enantiomers was 10.8% (s-ibuprofen) and 7.4% 
(r-ibuprofen) - Table 4.5. This compares favourably with the 10% variation of 
ibuprofen enantiomers obtained in the GC/MS assay procedure of Singh 40 . 
6.3.5.3.8 Sample Stability 
Whilst all samples in this current work were analysed within 12 hours of 
derivatization, the data (Table 4.6), clearly demonstrates that the influence of short 
term sample storage with regard to assay reproducibility is negligible. This is in 
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agreement with work by Testa5 who demonstrated a general degree of increased 
stability of diastereomeric amide derivatives over that of esters for bioanalytical 
work. 
6.4 KETOPROFEN 
6.4.1 HPLC Enantiomeric Assay 
6.4.1.1 Background 
An HPLC enantiomeric assay for ketoprofen was established (prior to the fore 
mentioned GC/MS assays), folowing guidelines previously set by Foster and 
Jamali41. The rationale for this was to: 
a) Reproduce the assay described in their publication with a view to 
modifying physical conditions in an atempt to enhance sensitivity for 
ketoprofen initialy 
and 	 b) To convert or modify the assay to alow measurement of ibuprofen 
enantiomers. 
6.4.1.2 Assay Sensitivity 
Numerous atempts to enhance sensitivity included variation of composition of the 
mobile phase and its pH, the substitution of alternative columns and substitution of 
the variable wavelength UV detector with a Waters fixed wavelength UV detector 
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Model 441 (used at various wavelengths between 250nm and 300nm). Despite these 
attempts, it was not possible to increase sensitivity to levels beyond 2Ong/mL for 
each enantiomer. A ten fold increase in sensitivity would be required for this assay 
to be suitable. A possible alternate means of enhancing sensitivity considered was to 
incorporate continuous - flow, post column derivatization (as used by Anhalt and 
Brown 44 in their HPLC assay of aminoglycoside antibiotics in serum). In their 
assay, o-phthalaldehyde was used to form fluorescent products for detection. It was 
subsequently determined that leucinamide derivatives of ketoprofen would be 
unlikely to readily react with such reagents54 , and so an alternative procedure was 
sought. 
6.4.2 Ketoprofen GC/MS Enantiomeric Assay 
A major incentive for the development of the fore mentioned ibuprofen GC/MS assay 
was to adapt it for the measurement of the free levels of ketoprofen enantiomers in 
synovial fluid, at much lower levels than achieved with the HPLC assay (6.4.1). 
Time constraints prevented refinement of the ketoprofen assay, however it was 
confirmed that standard curves for the procedure (within the required concentration 
range of 2-25ng/mL for each enantiomer) were possible. 
Whilst the lowest concentration of enantiomers assayed was Sng/mL, the data (Fig 
4.12) suggest that with refinement of procedure and optimisation of GC/MS 
conditions, measurement of ketoprofen enantiomers at 2ng/mL is feasible. 
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6.5 FACTORS AFFECTING NSAID BINDING  
6.5.1 NSAID Concentration 
6.5.1.1 Piroxicam 
The normal therapeutic range of piroxicam in plasma is 3 - 8 1g/mL26, and the 
corresponding synovial fluid levels will be approximately 40% of the plasma levels27 . 
There was a marked trend of piroxicam concentration-dependent HSA binding, (Fig 
5.1). Within the piroxicam concentration range 1 to 61.1g/mL ( and at an albumin 
concentration of 18g/L), the free drug fraction, F u increased from 0.69% to 1.29% 
respectively. 
The experiment was repeated with a sample of synovial fluid (Fig 5.2). The free 
fraction ranged from 3.5% - 5.5%, and was consistently higher than for the 18g/L 
albumin solutions over the same piroxicam concentration range. Whilst there are no 
published data comparing piroxicam binding in albumin solutions to synovial fluid, 
the current findings are consistent with previous studies, where the binding in 
synovial fluid and plasma (at comparable drug concentrations), were approximately 
98% and 99% respectively7. Chan et a190 found a similar trend in their studies with 
diclofenac, whilst contrary to these findings, Trnavska' and co-workers34 failed to 
detect any difference with piroxicam binding in synovial fluid and corresponding 
patient plasma. It is worth noting however, that they used much higher piroxicam 
concentrations (14.9 - 294tg/mL) than in the present study, which used 
concentrations more likely to be found in the clinical situation. 
6.5.1.2 Ibuprofen 
The fraction of ibuprofen enantiomers not bound to albumin (F u) increased 
significantly from a value of 0.00083 (r) and 0.0015(s) at lpg/mL to 0.0017(r) and 
0.0079(s) at 20i.tg/mL of r,s-ibuprofen. At all times, the free fraction of s-ibuprofen 
exceeded that of r-ibuprofen, (mean ratio s:r = 4.4 ± 1.15 S.D.) - Fig 5.3. 
The experiment was repeated using blank synovial fluid (previously assayed and 
found to contain 18g/L albumin). Fu increased from 0.0010 (r) and 0.0028 (s) at 
4p.g/mL r,s-ibuprofen to 0.0019 (r) and 0.0060 (s) at 30)_tg/mL. Free fractions of 
s-ibuprofen exceeded those of r-ibuprofen at all times (mean ratio s:r = 3.14 ± 0.19 
S.D.) - Fig 5.4. In the above studies, similar free fractional ratios of s - ibuprofen : r - 
ibuprofen were observed in albumin solution and synovial fluid ( at comparable drug 
concentrations). Hansen and co-workers 101 studied the plasma protein binding of 
ibuprofen enantiomers using equilibrium dialysis and observed a mean free fractional 
s:r ratio of 1.7:1 ± 0.29S.D. However, care must be exercised with extrapolation of 
their findings to the current work with HSA solutions as allied studies by Vowles and 
Marchant95 displayed a higher degree of ibuprofen binding to serum (or plasma) 
proteins compared to albumin solutions. Their work suggested that HSA was not a 
suitable model for human serum. 
6.5.1.3 Data Interpretation 
There are numerous difficulties involved with regard the analysis of results of binding 
experiments with relatively small NSAID molecules to proteins. In most instances, a 
theoretical model is used which plays a crucial role in terms of interpretation of the 
experimental results. Many authors have used the Scatchard equation (Equation 6.1), 
which was deduced from the law of mass action and from the probability of binding 
to a carier protein: 
n 	 k, C 
Equation 6.1 
i=1 
1 + Ici C 
where r is the average number of bound drug molecules per molecule of albumin, C is 
the free drug concentration, n is the number of binding sites and ki is the Scatchard 
site binding constant. In the simplest possible situation where it has been established 
unequivocaly by means other than binding measurements that there is only one 
receptor site, then it is reasonable to prepare a Scatchard plot (r / C vs r) of 
binding data and calculate the binding constant, ki . In practice however, many 
authors have atempted to decompose their complex, upward curved Scatchard plots 
into two or more independent components88. Furthermore, the number of classes of 
binding sites is often arbitarily chosen, based upon the minimum number of classes 
consistent with the observed experimental data83 - a procedure in itself which casts 
doubt upon the validity and significance of such values. Semi-logarithmic plots (log 
free drug vs moles of bound drug) of their Scatchard data should theoreticaly 
produce characteristic "S - shaped" curves. This rarely occurs, as the data for the 
upper part of the curves are usualy absent84. In practice, this happens because a point 
is reached where drug concentrations cannot be increased any further due to limited 
solubility or because the experiment must be terminated at a certain point for practical 
reasons82. An advantageous alternative85,89 can be the use of a stoichiometric binding 
description, such as the Klotz equation(Equation 6.2): 
kiC + 2k1k2C2 + 3k1k2k3C3 + 	 rik1k2.knCn 
= 	 Equation 6.2 
1 + kiC + k1k2C2 + ki k2k3C3 + 	 k1k2..k,Cn 
where k1 ..k are the set of stoichiometric binding constants82. 
Even so, within the confines and limitations of laboratory procedures for binding 
measurements, it becomes increasingly dificult to assign meaningful values to 
binding constants > k2 when dealing with multiple binding sites. The rationale for 
binding data analysis is seemingly reduced to the condensation of large quantities of 
experimental data to a smal number of parameters suitable for reconstruction of a 
binding curve. A more appropriate equation82 for the non-saturated binding studies in 
the curent work is Equation 6.3: 
r = 	 ( b2 C + 1 ) 	 Equation 63 
where bi and b2 are positive constants. 
An examination of the relation of these two constants to the Klotz equation (Equation 
6.2), where a plot of r vs C from Equation 6.3 has the same slope and curvature as a 
similar plot from Equation 6.2 alows calculation of the first and second 
stoichiometric binding constants ( k1 and k2) - Equation 6.4: 
ki ln [ 2 ( ki - 2k2 ) C + 1 ] 
= 	 Equation 6.4 
2 ( k1 - 2k2 ) 
where k > 2k2 
However, even these later equations (Equations 6.3 and 6.4) are essentialy 
descriptive models, which are merely mathematical tools with litle physiological 
meaning83. Monot and co-workers" described a global association function to 
characterize the apparent overal equilibrium of drug protein binding, and a binding 
transfer function to describe the relative rates of change in bound and free 
concentrations from the total concentration. There are two asymptotic approximation 
functions which have been proposed and used86: 
(i) The Trigonometric Model: B = al arctan ( a2 T) 	 Equation 6.5 
and 	 (i) The Exponential Model: B = b1 ( 1 - exp c- b2 T) ) Equation 6.6 
where B = concentration of bound drug, T = concentration of total drug and al and a2, bi and b2 are 
the two parameters of the models as determined from the experimental data. 
These two models are considered useful when the saturation limit of the bound 
concentration is unknown83. 
Preceeding data were compared to the fore mentioned models for goodness of fit, 
using FUNFIT®, (Fig 5.5 and Table 5.1). The data were well described by the 
Scatchard Model (assuming two classes of binding sites). Values for k l and k2 were 
about ten times higher than previously quoted in the literaturelw, whilst values for n 1 
and n2 were of similar order of magnitude, as previously estimated in plasma. The 
Larsen Model gave a poor fit to all experimental data, which was contrary to that 
predicted by the authors82 . Better fits were obtained with the Klotz model. This was 
expected, as there were a larger number of parameters that varied in the curve fitting 
procedure for the latter model. The k 2 values using the Klotz Model however, were 
too small to be meaningful. Similar values for k 1 to above were calculated using the 
Larsen / Klotz Model, whilst again, k2 values were extremely small. The two 
asymptotic functions (Trigonometric and Exponential Models) gave the best fits to the 
experimental data. Monot and co-workers 83 described these functions as being 
particularly useful when the saturation limit of the bound concentration is unknown. 
Values for k l , a l and b l were consistently greater in the piroxicam /HSA solutions 
compared to piroxicam in synovial fluid. This is consistent with previous studies by 
Monot et a1 83 using sodium salicylate, in which they found "the association function 
to be slightly less for synovial fluid than for plasma". Scatchard (k 1 ,k2), Klotz (k 1 ) 
and Larsen / Klotz (k 1 ) constants calculated for the current studies were slightly larger 
for r - ibuprofen in HSA solution compared to synovial fluid. The potential for r - 
ibuprofen to be displaced by endogenous substances present in synovial fluid may be 
a plausible explanation for these findings. This theory is also supportive of the 
generally higher association constant values obtained in fatty acid "stripped" albumin 
as compared to those in corresponding HSA solutions and synovial fluid. 
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6.5.2 Protein Concentration 
6.5.2.1 Background 
As outlined in chapter 1, albumin (the principle protein to which NSAID's bind at 
therapeutic levels) generally appears at a lower concentration in synovial fluid to 
plasma. From Table 1.2 it may be inferred that whilst synovial fluid albumin 
concentration will vary according to disease state, it generally would be expected to 
lie within the range llg/L (normal) to 30g/L (gout). 
6.5.2.2 Piroxicam 
When binding experiments were performed with piroxicam at an albumin 
concentration of lg/L there was no evidence of binding. Piroxicam, at a concentration 
of 21.tg/mL was highly bound to HSA ( 98.8% - Fig 5.6), at all other albumin 
concentrations studied, with only a small fraction present in the free form. Only at 
albumin concentrations less than 12g/L was there a more pronounced trend of 
albumin concentration - dependent binding. When the above procedure was repeated 
with diluted synovial fluid samples, higher fractions of unbound drug were present at 
comparable concentrations of albumin solutions, (Fig 5.7). Piroxicam binding 
remained independent of albumin concentrations over 12g/L. Also noteworthy was 
the two fold variation in free drug fractions of the synovial fluid samples examined. 
Interpatient variations of similar magnitude (with respect to binding in synovial fluid), 
were also noted by Trnavska' and co-workers34 . In their studies, binding of 
piroxicam (albeit at much higher concentrations; 15i.tg/mL), to protein in synovial 
fluid was the same as in corresponding patients' plasma. These researchers did not 
examine lower concentrations of piroxicam, presumably due to the limited sensitivity 
of their assay technique. 
6.5.2.3 Ibuprofen 
Experiments were conducted with r,s-ibuprofen (20pg/mL) mixed and incubated in 
the presence of blank HSA(Fraction V - CSL, Melbourne, Australia) in phosphate 
buffer, over a range of albumin concentrations typically found in synovial 
fluid (12-30g/L). At the r,s-ibuprofen concentration examined,the free fraction of 
both enantiomers were shown to be markedly dependent upon the albumin 
concentration. Fig 5.8 illustrates that enantiomers of ibuprofen (at the concentration 
studied), were highly bound to HSA (r-ibuprofen ?_ 99.7% ; s-ibuprofen ?_ 98.7%) 
within the albumin concentration range examined. At all times, the free fraction of 
s-ibuprofen was higher than the corresponding r-ibuprofen free fraction (mean s:r 
ratio = 3.40 ± 1.31 S.D.), which is consistent with the fore mentioned (6.5.1.3) 
findings of Hansen 101 . 
6.5.3 Chiral NSAID Enantiomer Ratio 
The well documented metabolic inversion of r - ibuprofen to s - ibuprofen 31 provided 
the basis for an in-vitro investigation of the effect on binding with increasing ratio of 
s : r - ibuprofen. The initial concentrations of r(-) - and s(+) - ibuprofen 
enantiomers were both 6pg/mL. As the concentration of s-ibuprofen was gradually 
increased, the free fractions of both enantiomers increased significantly from 
0.0012(r),0.0034(s) at 6pg/mL r + 6p.g/mL s - ibuprofen, to 0.0084(r), 0.0293(s) 
at 6pg/rnL r + 401.tg/mL s - ibuprofen (Table 5.2). Furthermore, at s-ibuprofen : 
r-ibuprofen ratios greater than 2:1, there was a dramatic increase in the free fractions 
of both enantiomers. The data is suggestive of incremental displacement of 
r-ibuprofen from low affinity binding sites with increasing concentrations of 
s-ibuprofen. This theory is consistent with the findings of Jones and co-workers 48 , 
whose studies with r,s-2PPA* in rabbit albumin suggested the possibility of a single 
saturable site of relatively low affinity (greater for r-2PPA than for s-2PPA) together 
with a capacity for non-specific binding that was also greater for r-2PPA. In the 
current work, r-ibuprofen was not increased in the presence of s-ibuprofen as this has 
never been shown to occur in vivo, however, Jones et a1 48 illustrated that the 
reverse situation does in fact occur with 2PPA. 
As the chiral NSAED's have relatively low hepatic extraction ratios, displacement of 
r - enantiomer from plasma and synovial fluid protein binding sites will lead to an 
increase in its clearance and volume of distribution 1 o4,105 . Lee et al33 noted the 
clearance of r - ibuprofen was greater when administered as part of the racemate, than 
when administered alone. Their data also suggested that s - ibuprofen was similarly 
affected by co-administration of the enantiomers. A plausible explanation for these 
observations may be competitive binding of the r(-) and s(+) enantiomers. Patients 
with renal dysfunction for example, will have a reduced net clearance of the r - and s 
enantiomers to their glucuronides. This would result in an increase in the 
pharmacologically active s - enantiomer, which in turn may be further increased due 
to metabolic inversion of the r - enantiomer to its s - counterpart. It is possible 
therefore, that in these patients, the effects could combine to produce elevated levels 
of the pharmacologically active species, with the likelihood of increases in both 
beneficial and unwanted effects 102 . 
enantiomers of r(-) - and s(+) - 2-phenylpropionic acid 
6.5.4 Fatty Acids 
6.5.4.1 Background 
Faty acids interact with different sites on the albumin molecule and have been 
demonstrated to have a variable influence on drug binding28,96. However, these 
interactions appear particularly prevalent on sites 1 and 2 where most NSAID's locate 
(Table 1.4). Whilst faty acid binding has been demonstrated to be remote from these 
two sites, it has been postulated that long chain faty acids bind at a location which is 
very close to site 2 and it is from there that they exert their alosteric effects, thus 
causing significant variability in terms of the nature and extent of associated drug 
binding28.110, 
There are numerous pathological, physiological and pharmacological conditions 
under which free faty acid concentrations vary as ilustrated in Table 6.3: 
Table 6.3: FACTORS AFFECTING FATTY ACID CONCENTRATIONSg 
Factor 	 [ Faty Acids I 
Meals 	 incnka ge 
Exercise 	 increase 
Pregnancy 	 increase 
Ethnicity 	 variable 
Myocardial infarct (acute) 	 increase 
Heparin 	 increase 
Cafeine 	 increasP 
Rheumatic Disease 	 incre_ase 
# adapted from Naranjo and Selers28 and Geigy Tables2 
6.5.4.2 Ibuprofen 
The unbound fraction of ibuprofen enantiomers in "stripped" albumin solution 
(1 8g/L) was examined. The free fraction of ibuprofen enantiomers increased 
significantly at concentrations above 20[1.g/mL of total r,s-ibuprofen, (Fig 5.9). There 
were insignificant differences in the s:r enantiomer ratios within the ibuprofen 
concentration range examined. In comparison to an earlier experiment using 
"unstripped" albumin (Fig 5.3), it was observed that whilst the extent of binding of 
r-ibuprofen is similar, s-ibuprofen is more highly bound in "stripped" albumin at 
comparable concentrations of racemic drug. The addition of oleic acid to "stripped" 
albumin was examined (Table 5.3). At molar ratios of oleic acid : albumin between 
3:1 and 4:1, noteworthy increases in free fractions of both enantiomers were observed 
at all concentrations of ibuprofen examined. 
No attempt at fitting parameters of best fit to a model of the interaction between oleic 
acid binding and combined specific and non-specific ibuprofen enantiomer to albumin 
was made as the number of parameters involved would be too large to be useful48 . 
However, the current observations are in agreement with those of Birkett et a1 97 who 
also noted significant inhibition of binding of similar drugs to albumin at oleic acid : 
albumin molar ratios of 3:1. Trnavska' et al34 , (whilst undertaking their binding 
studies with piroxicam), measured the content of free fatty acids in synovial fluid and 
plasma of patients with rheumatoid arthritis and noted molar ratios of free fatty acid 
to albumin were around 0.4: 1 for synovial fluid and 0.5 : 1 for plasma. They 
suggested that" in these conditions, inhibition of piroxicam binding by free fatty 
acids could not occur". These findings do not explain the current studies in which 
ibuprofen was more highly bound in "stripped" than "non-stripped" albumin, at a 
given drug concentration. Zona et a1 112 examined the influence of several 
environmental parameters on the binding of indomethacin and indoprofen to HSA. 
Their data suggested that "protein - drug binding is dependent upon the 
conformational status of the protein, and that it is favoured or permitted by relatively 
loose structure of the HSA". The above discrepancy may be a reflection of minor but 
significant conformational changes in the albumin "stripping" technique 49 . 103 . 
6.5.5 pH 
6.5.5.1 Background 
Whilst normal synovial fluid pH lies within the range 7.31-7.64, it is generally 
reduced with onset of inflammatory joint disease, presumably in connection with 
increased lactate concentration2 . It was therefore considered of interest to examine the 
effect of piroxicam binding in-vitro, (at drug / albumin / pH conditions typically 
found in normal and pathological synovial fluid). 
6.5.5.2 Study Using Piroxicam 
Piroxicam in HSA ((Fraction V - CSL) 18g/L in 0.067M Sorensen's phosphate 
buffer) was examined over the pH range 7.05-7.49, (typical of what occurs in 
pathological synovial fluid). 
In the current study, the protein binding of piroxicam (21.1g/mL), was independent of 
pH at an albumin concentration of 18g/L, (Table 5.4). This experiment was not 
repeated using synovial fluid over the same pH range due to practical difficulties in 
obtaining sufficient drug free samples from patients. Furthermore, there was concern 
that adjustment of synovial fluid pH to comparable values with exogenous agents may 
in some way interfere with the fluids' binding properties. However, earlier stability 
studies in this current work with piroxicam (2Rg/mL) in synovial fluid (Table 4.2) 
demonstrated insignificant free fractional fluctuation over the pH range : 7.45 - 7.95. 
Further experiments using synovial fluid pose problems, as alteration of pH in 
isolation of other physical or environmental factors (such as ppCO2, pp02 etc), have 
the potential to introduce undesirable variation to subsequent free fraction 
calculations. 
CHAPTER 7 
OVERVIEW AND FUTURE WORK 
7.1 PROTEIN BINDING DETERMINATIONS 
In this current work, the Amicon MPS-1 ultrafiltration device provided rapid and 
consistent separation of unbound NSAID in synovial fluids and HSA solutions. 
Radiolabel led piroxicam provided a convenient and relatively, simple means of 
investigating the protein binding characteristics of this drug in synovial fluid.A 
major drawback with using a radiolabelled NSAID as a marker for subsequent 
binding studies may occur when the specific activity of the radiolabelled material is 
too low to enable a synovial fluid sample (containing the NSAID) to be "spiked" 
with radiolabelled drug, without causing a significant alteration to the initial drug 
concentration in the fluid, prior to determination of the unbound drug fraction. 
From a practical viewpoint, the above radiolabelling procedure was inappropriate for 
examination of the binding characteristics of ibuprofen and ketoprofen enantiomers 
in these laboratories. An assay of sufficient sensitivity and reproducibility was 
therefore developed to measure the extremely low levels of unbound drug 
enantiomers expected in these fluids. 
The TLC/HPLC assay system established to monitor the radiochemical purity of 
the radiolabelled 3H piroxicam was relatively simple and rapid, and considered 
necessary to eliminate potential sources of experimental error in the calculation of 
free drug fractions. The specific activity of the radiolabelled material was sufficiently 
high to enable ultrafiltration binding experiments to be performed with small 
volumes of prefiltrate (5 lmL) within a range of piroxicam concentrations typically 
found in synovial fluid, (1-71.1g/mL). The coefficient of variation of the procedure 
(using the Amicon MPS-1 ultrafiltration device), was 5 9.8%. 
The GC/MS assay procedure developed, allowed resolution of ibuprofen 
enantiomers at concentrations of 2ng/mL with a coefficient of variation of 5 10.8% 
and 5 7.4% for s-ibuprofen and r-ibuprofen respectively. 
The entire procedure (complete in a matter of minutes), is in marked contrast to the 
more lengthy methods found in the literature. The assay was readily adaptable to 
allow resolution of ketoprofen enantiomers. Whilst this ketoprofen assay was left 
at a relatively early stage of development, it became abundantly clear from the data 
that with refinement of procedure and GC/MS conditions, measurement of 
ketoprofen enantiomers at 2ng/mL (or possibly lower) is feasible. 
7.2 SUMMARY OF FINDINGS 
The clinical pharmacolcinetic properties of NSAID's are markedly influenced by the 
affinity and extent of their protein binding properties in plasma and synovial fluid. 
Whilst the total level of NSAID is dependent upon concentration and affinity of local 
protein, it is the unbound / free fraction that is the species which readily diffuses 
between plasma and synovial fluid. It is therefore not suprising that the free fraction 
of these drugs at or near the presumed site of action continue to attract much interest. 
From the outset, a major strategy with the current work was to ensure all parameters 
of the in-vitro studies were as representative of the situation in-vivo as practically 
possible (with respect to protein concentration, NSAID concentration and associated 
environmental conditions of temperature, pH etc). The current studies concentrated 
on the influence of several physical factors thought to influence the in-vitro protein 
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binding of piroxicam and ibuprofen in synovial fluid and/or HSA solutions(at 
albumin concentrations typically found in normal or pathological synovial fluid). 
The free fractions of piroxicam and ibuprofen enantiomers were found to be 
markedly dependent upon their respective drug and associated albumin 
concentrations in synovial fluid according to pre-determined physical conditions. 
One should exercise caution with interpretation of binding constants determined 
from experimental data as most of the commonly calculated values are based on 
saturation functions such as those described by Scatchard and Klotz 83 .Consideration 
should also be given to alternative mathematical functions when interpreting the 
results of non-saturated binding studies 83 . 
Binding of piroxicam was found to be independent of pH at concentrations of drug 
and albumin typically found in synovial fluid, whilst similar studies (albeit a small 
population sample over a somewhat higher range of pH) in samples of pathological 
synovial fluids also supported this finding. 
7.3 FUTURE ISSUES 
7.3.1 Determinants of NSAID Free Fraction 
Clearly current and previous studies leave many questions unanswered. Physical 
and environmental factors play primary roles with regard to the binding affinities of 
NSAlD's in synovial fluid and plasma. Other factors such as pp02 , ppCO2 , 
temperature and other biochemical/serological functions should be examined.These 
factors should be examined not only in isolation, but also as a composite mix, (as 
expected in-vivo). However, there are numerous practical problems to be overcome 
in designing such studies. For example, partial pressures of synovial fluid gases 
101 
would be expected to change rapidly following collection from a patient, and these 
shifts may cause difficulties with protein binding experiments monitoring one 
variable at a time. 
7.3.2 Can NSAID Levels be Correlated with Clinical Response? 
Despite isolated reports 106 of a positive relationship between plasma NSAID 
concentration and therapeutic effect, the majority of studies have been disappointing. 
As synovial fluid is close to the target tissue where a NSAID's effect is exerted, it is 
reasonable to expect its concentration in this fluid to be a better indicator of drug 
activity in rheumatic disease than in plasma. However, before an attempt to 
correlate synovial fluid NSALD concentration with clinical response can be made, 
further characterisation of the protein binding of the whole class of these drugs in 
synovial fluid may be beneficia1 70 . 
Furthermore, it is essential to examine the free levels of active enantiomer of chiral 
NSAID's in synovial fluid, because interindividual differences in metabolic 
inversion could lead to erroneous results if enantiospecific differentiation were 
ignored in the assay procedures. Despite the fact that the enantiomers of the 
2-arylpropionic acid NSALD's differ in pharmacological properties, we are still 
witnessing articles in the literature that generate data of a non stereospecific 
nature98,113 . In addition, such studies would require consideration of individual 
differences in NSAID disposition of both drug and its active metabolites. 
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APPENDIX 
APPENDIX 
1. SELECTION OF PATIENTS 
1.1 Inclusion Criteria  
Male or female adult patients with effusions into the knee of either 
mechanical or inflammatory origin. 
1.2 Exclusion Criteria  
- Patients with severe renal or hepatic disease. 
- Manifest cardiac insufficiency or severe hypertension. 
- Patients under treatment with oral anticoagulants. 
- Patients under treatment with corticosteroids. 
- Malabsorption syndrome or any other g.i. condition likely to affect drug 
absorption. 
- Pregnant women or women actively seeking pregnancy. 
- Concomittant NSAID therapy. 
- Concomittant therapy with Salazopyrin. 
- Treatment with aspirin or any other NSAID within 48 hours (or 6 drug 
half-lives : whichever is the greater), prior to recruitment. 
- Patients with hepatitis or HIV antibodies. 
2. PROCEDURE 
2.1 The collection of such samples will be via retrieval of excess synovial fluid 
remaining after routine non-trial related patient care.This procedure will 
eliminate unnecessary and invasive sampling of body fluids. 
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2.2 The volume of synovial fluid collected will vary with the extent of the 
effusion, and shall be an amount as deemed appropriate to normal patient 
care. 
3. METHOD 
Synovial fluid samples will be collected according to the method of Day et al* 
and stored at 4°C until assayed. 
4. CONCOMITANT MEDICATIONS / THERAPY 
- Any other non-steroidal anti-inflammatory agent is strictly prohibited for 48 
hours or six drug half-lives, (whichever is the greater) prior to sample 
collection. 
- Paracetamol will be permitted as an analgesic, if required. 
- Patients on chronic therapy with specified drugs considered not to interfere with 
NSAID protein binding may be included. 
5. ANALYSIS OF DATA 
•The data will be analysed by Pharmacy School, University of Tasmania (D. Jack / • 
R. Rumble), and a report generated, suitable for publication. 
6. FUNDING 
This study is totally funded by the School of Pharmacy / University of 
Tasmania and external grants. No costs to the hospital or institution will be 
incurred. 
Day RO, Williams RM, Lee EJD, Knihinicki RD and Graham GG. The 
Stereoselective Disposition of the Enantiomers of Ibuprofen in Synovial Fluid. 
Agents Actions[Suppl] 1985;17. 
104 
REFERENCES 
REFERENCES 
1. Cohen A.S. Laboratory Diagnostic Procedures in the Rheumatic Diseases, 
(Little, Brown & Company - Boston) : 1-50, (1967). 
2. Geigy Scientific Tables Ciba-Geigy Ltd, Basle,Switzerland, 8th 
Edn, (1981). 
3. Ogston A.G, Phelps C.F. The Partition of Solutes between Buffer Solutions 
and Solutions Containing Hyaluronate. Biochem J. 78: 827, (1981). 
4. Binette J.P, Schmid K. The Proteins of Synovial Fluid : A Study of the 
Alpha 1 / Alpha 2 Globulin Ratio. Arthritis Rheum. 8: 14, (1965). 
5. Furst D. Synovial Fluid Kinetics of Non Steroidal Anti-Inflammatory Drugs: 
Agents Actions. Suppl. 17 : 65-78, (1985). 
6. Sallis J.G,Perry J. Absorption from the Synovial Cavity in Rabbits and Cats. 
The Influence of Different Environments and Drugs. Sth Afr.J.Med.Sci. 
32, 83-95, (1967). 
7. Fenner H. Pharmacokinetics of Piroxicam - New Aspects: Eur. J. Rheum. & 
Inflamm. 8, 42-48, (1985). 
8. Gronlund C, Marketing Planning Manager, Ciba - Geigy Australia Limited, 
Private Communication, (1987). 
9. Non Steroidal Anti-Inflammatory Drugs: New Perspectives in the 
Inflammatory Process and Immunological Function. Proceedings of a 
symposium. Am. J. Med. 77:1-31, (1984). 
10. Wanwitnolruk S,Brooks P.M,Birkett D.J. Protein Binding of Non Steroidal 
Anti-Inflammatory Drugs in Plasma and Synovial Fluid of Arthritic Patients. 
Br.J.Clin.Pharmacol. 15, 91-94, (1983). 
11. Gray P. Glatt M, Brune K. Acidic Non Steroidal Anti-Inflammatory Drugs 
Accumulating in Inflammed Tissue. Experientia 31: 951-953, (1985). 
105 
12. Wallis W.J, Simkin P.A. Antirheumatic Drug Concentrations in Human 
Synovial Fluid and Synovial Tissue. Clin Pharmacokinet. 8 : 496-522, 
(1983). 
13. Ballantyne F.C, Fleck A, Dick W.C. Albumin Metabolism in Rheumatoid 
Arthritis. Ann.RheumDis. 30 :265-270, (1971). 
14. Denko C.W, Purser D.B, Johnson R.M. Amino Acid Composition of Serum 
. Albumin in Normal Individuals and in Patients with Rheumatoid Arthritis. 
Clin.Chenz. 16: 54-57, (1970). 
15. Wanwimolruk S, Birkett D.J, Brooks P.M. Protein Binding of some Non 
Steroidal Anti-Inflammatory Drugs in Rheumatoid Arthritis. Clin 
Pharmacokinct. 7: 85-92, (1982). 
16. Costello P.B, Green F.A, Jung C.Y. Free versus Bound Salicylate 
Concentration in Adults and Children with Chronic Inflammatory Joint 
Disease. Arthr.Rheum. 25 : 32-37, (1982). 
17. Meloun B, Moravek L, Kostka V. Complete Amino Acid Sequence of 
Human Serum Albumin. FEBS Lett. 58: 134-137, (1975). 
18. Brown JR. in Albumin,Structure,Function and Uses: Rosenoer V.M, 
Orutz M, Rothschild M.A. Eds. (Pergamon Press - Oxford): 27, (1977). 
19. Sjoholm I. The Specificity of Drug Binding Sites on Human Serum Albumin. 
in Drug - Protein Binding, (Praeger Press - New York): 36-45, (1984). 
20. Sudlow G, Birkett D.J, Wade D.N. Further Characterisation of Specific 
Drug Binding Sites on Human Serum Albumin. Mol .Pharmacol. 12, 
1052-1061, (1976). 
21. Wanwimolruk S, Birkett DJ, Brooks P.M. Structural Requirements for 
Drug Binding to Site 2 on Human Serum Albumin. Mol. Pharmacol. 24, 
458-463, (1983). 
22. Kurz H. Methodological Problems in Drug Binding Studies. in Drug Protein 
Binding. (Praeger Press) Clin.Pharmacol. &Ther. series. 6: 70-92. 
106 
23. Williams K.M, Day R.0, Murphy R, Currenti F, Graham S: Poster 
presentation: A.S.C.E.P. Scientific Meeting, Adelaide, Australia, 
(1988). 
24. Whitlam J.B, Brown K.F. Ultrafiltration in Serum Protein Binding 
nPterminntir■ns..I.Phfirm.cci . 70, 2,146-150, (Feb 1981). 
25. Nies K.M. in Principles of Synovial Fluid Analysis in Rheumatology. 
Bluestone R. ed. (Houghton Mifflin Professional Publishers, Medical 
Division, Boston): 27: 322-327, (1975). 
26. Drug Information '85.American Hospital Formulary Service, Bethesda. 
American Society of Hospital Pharmacists Inc., (1985). 
27. Martindale - The Extra Pharmacopoeia. 29th Edition, Pharmaceutical Press, 
London, (1989). 
28. Naranjo C.A, Sellers E.M. in Drug Protein Binding: (Praeger Press - New 
York): 18: 233-253, (1986). 
29. Moore D.H. Clinical and Pharmacological Applications of Electrophoresis. in 
Electrophoresis: Theory, Methods, and Applications.. (Academic Press Inc, 
New York) 369-425, (1959). 
30. Lederer M. An Introduction to Paper Electrophoresis and Related Methods: 
Elsevier Publishing Co, (1955). 
31. Hutt A.J, Caldwell J. The Metabolic Chiral Inversion of 2-Arylpropionic 
Acids - A novel Route with Pharmacological Consequences 
J.Pharm.Pharmacol. 35: 693-704, (1983). 
32. Testa B. Chiral Aspects of Drug Metabolism: Tips. 60-64, (Feb.1986). 
33. Lee E.J.D, Williams K, Day R, Graham G, Champion D. Stereoselective 
Disposition of Ibuprofen Enantiomers in Man. Br.J.Clin.Pharmacol. 19: 
669-674, (1985). 
107 
34. Trnavska Z, Trnavsky T, Zlnay D. Binding of Piroxicam to Synovial Fluid 
and Plasma Proteins in Patients With Rheumatoid Arthritis. 
Eur.J.Clin.Pharmacol. 26: 457-461, (1984). 
35. Kurowslci M, Dunky A. Transynovial Kinetics of Piroxicam in Patients With 
Rheumatoid Arthritis. Eur.J.Clin.Pharmacol. 34: 401-406, (1988). 
36. Geisslinger G, Dietzel K. High Performance Liquid Chromatographic 
Determination of Ibuprofen,Its Metabolites and Enantiomers in Biological 
Fluids. J.Chromatogr. 491: 139-149, (1989). 
37. Avgerinos A, Hutt A.J. Determination of the Enantiomeric Composition of 
Ibuprofen in Human Plasma by High Performance Liquid Chromatography. 
J.Chromatogr. 415: 75-83, (1987). 
38. Kaiser D.G, Van Giessen G.J. GLC Determination of Ibuprofen 
[( )-2-(p-Isobutylphenyl) propionic Acid] in Plasma. J.Pharm.Sci. 63: 
219-221, (1974). 
39. Lee E.J.D, Williams K.M, Graham G.G, Day R.0, Champion G.D. Liquid 
Chromatographic Determination and Plasma Concentration Profile of Optical 
Isomers of Ibuprofen in Humans. J.Pharm.Sci. 73: 1542-1544, (1984). 
40. Singh N.N, Pasutto F.M, Coutts R.T, Jamali F. Gas Chromatographic 
Separation of Optically Active Anti-Inflammatory 2-Arylpropionic Acids 
Using (+)- or (-)- Amphatamine as Derivatizing Reagent. J.Chromatogr. 
378: 125-135, (1986). 
41. Foster R.T, Jamali F. High Performance Liquid Chromatographic Assay of 
Ketoprofen Enantiomers in Human Plasma and Urine. J.Chromatogr. 416: 
388-393, (1987). 
42. Bjorkman J. Determination of the Enantiomers of Indoprofen in Blood 
Plasma by High Performance Liquid Chromatography After Rapid 
Derivatization by Means of Ethylchloroformate. J.Chromatogr. 339: 
339-346, (1985). 
108 
43. 	 Royer R.J, Lapicque F, Neter P, Monot C, Bannwarth B, Cure M.C. 
Estimation by High Performance Liquid Chromatography of Ketoprofen in 
Plasma. Application to the Study of its Protein Binding. 
Biomed.Pharmacother. 40: 100-105, (1986). 
AA 	 Anhalt J.P, Brown S.D. High-Performance Liquid-Chromatographic Assay 
of Aminoglycoside Antibiotics in Serum. Clin.0 hem. 24,11: 1940-1947, 
(1978). 
45. Kaiser D.G, Vangiessen G.J, Reischer R.J, Wechter W.J. Isomeric 
Inversion of Ibuprofen(R)-Enantiomer in Hurnans.J.Pharm.Sci. 65: 
269-273, (1976). 
46. Owen S. Response in Rheumatoid Arthritis. Ph.D. Thesis, University of 
Tasmania (1986). 
47. Grob k, Muler E. Sample Reconcentration by Column - External Solvent 
Evaporation or Injection of Large Volumes into Gas Chromatographic 
Capilary Columns. J.Chromatogr. 404: 297-305, (1987). 
48. Jones M.E, Salustio B.C, Purdie Y.J, Meffin P.J. Enantioselective 
Disposition of 2-Arylpropionic Acid Nonsteroidal Anti-Inflammatory Drugs. 
II 2-Phenylpropionic Acid Protein Binding. J.Pharmacol.Exp.Ther. 
238,1:288-294, (1986). 
49. Chen R.F. Removal of Faty Acids from Serum Albumin by Charcoal 
Treatment. J.Biol.0 hem. 242: 173-181, (1967). 
50. Richardson C.J, Ross S.G. High Performance Liquid Chromatographic 
Analysis of Piroxicam and its Major Metabolite 5'-Hydroxypiroxicam in 
Human Plasma and Urine. J .Chromatogr. 382: 382-388, (1986). 
51. Macek J, Vacha J. Rapid and Sensitive Method for Determination of 
Piroxicam in Human Plasma by High Performance Liquid Chromatography. 
J.Chromatogr. 420: 445-449, (1987). 
109 
52. Twomey T.M, Bartolucci S.R, Hobbs D.C. Analysis of Piroxicam in Plasma 
by High Performance Liquid Chromatography. J.Chromatogr. 183: 104-108, 
(1980). 
53. Day R.0, Williams K.M, Graham G.G, Lee E.J, Knihinicki R.D, Champion 
D. Stereoselective Disposition of Ibuprofen Enantiomers in Synovial Fluid. 
Clin.Pharmacol..Ther. 43: 480-487, (1988). 
54. Bremner J.B. Chemistry Department, University of Tasmania. Private 
Communication, (1988). 
55. Testa B. The Chromatographic Analysis of Enantiomers in Drug Metabolism 
Studies. Xenobiotica 16:265-279, (1986). 
56. Sallustio B.C, Abas A, Hayball P.J, Purdie Y.J, Meffin P.J. Enantiospecific 
High Performance Liquid Chromatographic Analysis of 2- Phenylpropionic 
Acid, Ketoprofen and Fenoprofen. J.Chromatogr. 374: 329-337, (1986). 
57. Wainer I.W, Doyle T.D. Application of High Performance Liquid 
Chromatographic Chiral Stationary Phases to Pharmaceutical Analysis : 
Structural and Conformational Effects in the Direct Enantiomeric Resolution 
of Alpha - Methylarylacetic Acid Anti-Inflammatory Agents. J.Chromatogr. 
284:117-124, (1984). 
58. Goto J, Goto N, Nambara T. Separation and Determination of Naproxen 
Enantiomers in Serum by High Performance Liquid Chromatography. 
J.Chromatogr. 239: 559-564, (1982). 
59. Verbeeck R.K, Blackburn J.L, Loewen G.R. Clinical Phamiacokinetics of 
Non-Steroidal Anti-Inflammatory Drugs. Clin Pharmacokinet. 8: 297-331, 
(1983). 
60. Dittrich P, Kohler G, Primbs P, Kukovetz W.R. Pharmacokinetics of 
Indomethacin I.M. in Blood, Synovial Fluid, Synovial Membrane, Muscle, 
Fat, Bone and Spinal Fluid. Eur. J. Rheum. Inflam. 7: 45-50, (1984). 
110 
61. Swanson B.R, Day R.0, Williams K.M. The Assay of Unbound and Total 
Concentrations of Tenoxicam in Synovial Fluid and Plasma. Poster 
Presentation A.S.C.E.P. Scientific Meeting, Hobart, Tasmania Australia, 
(1987). 
62. Mehvar R, Jamali F, Pasutto F. Rapid and Sensitive High Performance 
Liquid Chromatographic Assay of Tiaprofenic Acid Enantiomers in Human 
Plasma and Urine. J.Chromatogr. 425: 135-142, (1988). 
63. Szabolcs A, Szammer J, Noszko L. A New Method for the Preparation of 
Carboxyl - Labelled Aliphatic Carboxylic Acids. Tetrahedron 30: 3647-3648, 
(1974). 
64. Dauben W.G, Reid J.C, Yankwich P.E, Calvin M. in Organic Synthesis 
with Isotopes (Phenylacetic - 1 - C 14 Acid), 72, (1958). 
65. Nies K.M. Principles of Synovial Fluid Analysis. in Rheumatology. 
(Houghton Mifflin Prof.Publishers, Boston): 323-327, (1975). 
66. Schumacher H.R, Siek M.S, Rothfuss S, Clayburne G.M, Baumgarten D.F, 
Mochan B.S, Kant J.A. Reproducibility of Synovial Fluid Analyses. A 
Study Among Four Laboratories. Arth.Rheum. 29, 6: 770-774, (1986). 
67. Richardson C.J, Blocka K.L.N, Ross S.G, Verbeeck R.T, Verbeeck R.K. 
Effects of Age and Sex on Piroxicam Disposition. Clin.Pharmacol.Ther.37: 
13-18, (1985). 
68. Svensson C.K, Woodruff M.N, Baxter J.G, Lalka D. Free Drug 
Concentration Monitoring in Clinical Practice. Rationale and Current Status. 
Clin Pharmacokinet. 11: 450-469, (1986). 
69. Woodhouse K.W, Wynne H. The Pharmacokinetics of Non-Steroidal 
Anti-Inflammatory Drugs in the Elderly. Clin.Pharmacokinet. 12: 111-122, 
(1987). 
70. Netter P. Bannwarth B, Royer-Morrot M.J. Recent Findings on the 
Pharmacokinetics of Non-Steroidal Anti-Inflammatory Drugs in Synovial 
Fluid. Clin.Pharmacokinet. 17(3): 145-162, (1989). 
111 
71. Williams K, Lee E. Importance of Drug Enantiomers in Clinical 
Pharmacology. Drugs 30: 333-354, (1985). 
72. Fowler P.D, Shadforth M.F, Crook P.R, John V.A. Plasma and Synovial 
Fluid Concentrations of Diclofenac Sodium and its Major Hydroxylated 
Metabolites During Long Term Treatment of Rheumatoid Arthritis. 
Eur.J.Clin.Pharmacol. 25: 389-394, (1983). 
73. Birkett D.J. The Importance of Unbound Drug. Agents and Actions. 
Supplement 17: 79-84, (1985). 
74. Svensson C.K, Woodruff M.N, Lalka D. Influence of Protein Binding and 
Use of Unbound (Free) Drug Concentrations. in Applied Pharmacokinetics 
Applied Therapeutics Inc. 187-219, (1987). 
75. Tietz N.W. in Fundamentals of Clinical Chemistry. W.B. Saunder & Co, 
Phil, USA, (1985). 
76. Candlish J.K, Koay E.S.C, Aw T.C. in ASTRA Tests. National University 
Hospital, (1987). 
77. Australian Pharmaceutical Formulary and Handbook. 12th Edition (Griffin 
Press, S.Australia): 250, (1978). 
78. Hutt A.J, Caldwell J. The Importance of Stereochemistry in the Clinical 
Phannacokinetics of the 2-Arylpropionic Acid Non-Steroidal 
Anti-Inflammatory Drugs. Clin.Pharmacokinet. 9:371-373, (1984). 
79. Adams S.S, Bresloff P, Mason C.G. Pharmacological Differences between 
the Optical Isomers of Ibuprofen: Evidence for Metabolic Inversion of the (-)- 
Isomer. J.Pharm.Phamacol. 28:256-257, (1976). 
80. Cox J.W, Cox S.R, Van Giessen G, Ruwart M.J. Ibuprofen Stereoisomer 
Hepatic Clearance and Distribution in Normal and Fatty in Situ Perfused Rat 
Liver. J.Pharmacol.Exp.Ther. 232,(3):636-643, (1985). 
112 
81. Meffin P.J, Ahern M.J, Purdie Y.J. Enantioselective Disposition of 
Ketoprofen in Man. Poster Presentation, A.S.C.E.P. Scientific Meeting, 
(1986). 
82. Larsen C.G, Larsen F.G, Brodersen R. A Two Constant Equation for 
Multiple Albumin Binding Isotherms. J.Pharm.Sci. 75: 669-671, (1986). 
83. Monot C, Neter P, Benamghar L, Lapicque F, Bannwarth B, Martin J. 
Association and Transfer Functions for Analysis of Drug Binding to 
Proteins. J.Pharm.Sci.75: 590-595, (1986). 
84. Klotz I.M. Numbers of Receptor Sites from Scatchard Graphs: Facts and 
Fantasies. Science 217: 1247-1249, (1982). 
85. Klotz I.M, Hunston D.L. Protein Afinities for Smal Molecules: 
Conceptions and Misconceptions. Arch.Biochem.Bioplysics 193: 314-328, 
(1979). 
86. Monot C, Neter P, Stalars M.C, Martin J, Royer R.J, Gaucher A. 
Dificulties in Applying the Scatchard Model of Ligand Binding to Proteins - 
Proposal of New Mathematical Tools - Application to Salicylates. 
J.Pharm.Sci. 72: 35-41, (1983). 
87. Fletcher J.E, Spector A.A. Alternative Models for the Analysis of Drug - 
Protein Binding. Molecular Pharmacol. 13: 387-399, (1977). 
88. Norby J.G, Otolenghi P, Jensen J. Scatchard Plot: Common 
Misinterpretation of Binding Experiments. Analytical Biochem. 102: 
318-320, (1980). 
89 	 Honore' B, Brodersen R. Albumin Binding of Anti-inflammatory Drugs. 
Utility of a Site - Oriented versus a Stoichiometric Analysis. Molecular 
Pharmacol. 25: 137-150, (1984). 
90. 	 Chan K.K.H, Vyas K.H, Brandt K.D. In Vitro Protein Binding of 
Diclofenac Sodium in Plasma and Synovial Fluid. J.Pharm. Sci. 76, 2: 
105-108, (1987). 
113 
91. Li K.L, Thalcur A.K, Kapoor A.L. Structural Requirements for Binding of 
Nonsteroidal Anti-inflammatory Drugs to Human Serum Albumin. J.Pharm 
Sci. 77: 251-254, (1988). 
92. Lockwood G.F, Albert K.S, Szpunar G.J, Wagner J.G. Pharmacolcinetics 
of Ibuprofen in Man - Plasma Protein Binding. JI.Pharmacokinetiliopharm. 
11: 469-482, (1983). 
93. Guentert T.W, Oie S. Factors Influencing the Apparent Protein Binding of 
Quinidine. J.Pharm.Sci. 71: 325-328, (1982). 
94. Re'ndic S, Alebic'-Kolbah T, Kajfez F. Binding of Piroxicam to Human 
Serum Albumin. Acta.PharmJugosl. 31: 215-220, (1981). 
95. Vowles D.T, Marchant B. Protein Binding of Ibuprofen and its Relationship 
to Drug Interaction. Br.J.Clin.Pract. Suppl 6: 13-19, (1979). 
96. Rudman D, Bixler T.J, Del Rio A.E. Effect of Free Fatty Acids on Binding 
of Drugs by Bovine Serum Albumin, by Human Serum Albumin and by 
Rabbit Serum. J.Pharmacol.Exp.Ther. 176: 261-272, (1971). 
97. Birkett DJ, Myers S.P, Sudlow G. Effects of Fatty Acids on Two Specific 
Drug Binding Sites on Human Serum Albumin. Mol.Pharmacol. 13: 
987-992, (1977). 
98. Foster R.T, Jamali F, Russell A.S. Ketoprofen Enantiomers in Synovial 
Fluid. J.Pharm.Sci. 78: 881-882, (1989). 
99. Amicon Scientific, Fawlcner, Victoria, Australia. Technical Service 
Communication, (1986). 
100. Veng-Pedersen P.J. Curve Fitting and Modelling in Pharmacokinetics and 
Some Practical Experiences with NONLIN and a New Program FUNFIT. 
J.Pharmacokinet.Biopharm. 5: 513, (1977). 
101. Hansen T, Day R, Williams K, Lee E, Knihinicki R, Duffield A. Abstract # 
153 at A.S.C.E.P. Scientific Meeting, (1984). 
114 
102. Meffin P.J, Sallustio B.C, Purdie Y.J, Jones M.E. Enantioselective 
Disposition of 2-Arylpropionic Acid Non-Steroidal Anti-inflammatory Drugs. 
2-Phenylpropionic Acid Disposition. J.Pharmacol.Exp.Ther. 238: 280-287, 
(1986). 
103. Whitlarn J. 13, Crooks M.J, Brown K.F, Veng-Pedersen P. Binding of Non 
Steroidal Anti-Inflammatory Agents to Proteins. Ibuprofen - Serum Albumin 
Interaction. Biochem.Pharmacol.. 28: 675-678, (1978). 
104. Aarons L, Grennan D.M, Siddiqui M. The Binding of Ibuprofen to Plasma 
Proteins. Eur.J.Clin.Pharmacol. 25: 815-818, (1983). 
105. Wilkinson G.I2, Shand D.G. A Physiological Approach to Hepatic Drug 
Clearance. Clin.Pharmacol.Ther. 18: 377-384, (1975). 
106. Day R.0, Furst D.E, Dromgoole S.H, Kramm B, Roe R. Relationship of 
Serum Naproxen Concentration to Efficacy in Rheumatoid Arthritis. 
Clin.Pharmacol.Ther. 31:733-740, (1982). 
107. Lin J.H, Cocchetto D.M, Duggan D.E. Protein Binding as a Primary 
Determinant of the Clinical Pharmacoldnetic Properties of Non-Steroidal 
Anti-Inflammatory Drugs. Clin.Pharmacokinet. 12: 402-432, (1987). 
108. Mason S. The Origin of Chirality in Nature. Tips. 20-23, (Jan. 1986). 
109. Walle T, Walle U.K. Pharmacokinetic Parameters Obtained with Racemates. 
Tips. 155-158, (Apr. 1986). 
110. Trnavska"Z, Trnavsky"K. Characterization of Salicylate Binding to 
Synovial Fluid and Plasma Protein in Patients with Rheumatoid Arthritis. 
Eur.J.Clin.Pharmacol. 18: 403-406, (1980). 
111. Drayer D.E. Problems in Therapeutic Drug Monitoring : The Dilemma of 
Enantiomeric Drugs in Man. Ther.Drug.Monitoring. 10: 1-7, (1988). 
112. Zona C, Roscetti G, VentureIli F, Roda L.G. Effect of Different Parameters 
on the Binding of Two Anti-Inflammatory Drugs to Human Serum Albumin. 
Pharmacol.Biochem. Behav. 24: 1031-1037, (1986). 
115 
113. 	 Ariens E.J. Stereochemistry, a Basis fOr Sophisticated Nonsense in 
Pharmacokinetics and Clinical Pharmacology. EurJ.Clin.Pharmacol. 26: 
663-668, (1984). 
116 
